repaglinide has been researched along with Diabetes Mellitus, Adult-Onset in 259 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 43 (16.60) | 18.2507 |
| 2000's | 138 (53.28) | 29.6817 |
| 2010's | 66 (25.48) | 24.3611 |
| 2020's | 12 (4.63) | 2.80 |
| Authors | Studies |
|---|---|
| Ouazzani, J; Sasaki, NA; Sergent, D; Wang, Q | 1 |
| Washburn, WN | 1 |
| Li, Y; Wang, X; Zhang, Y | 1 |
| Bayram, C; Cetin, M; Hacimuftuoglu, A; Kaplan, ABU; Taghizadehghalehjoughi, A; Yildirim, S | 1 |
| Furton, KG; Gennimata, D; Kabir, A; Panderi, I; Parla, A; Samanidou, V; Stamou, P | 1 |
| Fukui, M; Hasegawa, G; Hirata, A; Kadono, M; Nakajima, H; Okada, H; Okada, Y; Oyamada, H; Tanaka, M; Yamane, T | 1 |
| Pishdad, GR; Pishdad, P; Pishdad, R | 1 |
| Gnesin, F; Hemmingsen, B; Kähler, LKA; Madsbad, S; Thuesen, ACB | 1 |
| Panahi, Y; Pishdad, GR; Pishdad, P; Pishdad, R | 1 |
| Jain, AK; Jain, SK; Mishra, K; Sahu, P | 1 |
| Chi, Y; Hemmingsen, B; Ipsen, EØ; Madsen, KS; Metzendorf, MI; Pedersen-Bjergaard, U; Richter, B | 1 |
| Fujii, K; Hazama, Y; Kosugi, M; Miyoshi, Y; Nagata, S; Obata, Y; Takayama, K; Uehara, Y; Yamaguchi, H; Yasuda, T | 1 |
| Chen, X; Chen, Y; He, S; Li, G; Qian, X; Shen, X; Xu, X; Zhang, B | 1 |
| Bilker, WB; Brensinger, CM; Flory, JH; Hee Nam, Y; Hennessy, S; Leonard, CE | 1 |
| Bezemer, ID; Bianchini, E; Blin, P; Hall, GC; Hammar, N; Heintjes, EM; Herings, RMC; Lapi, F; Lassalle, R; Overbeek, JA; Prieto-Alhambra, D | 1 |
| Areosa Sastre, A; González-Colaço Harmand, M; Martínez, G; Vernooij, RW | 1 |
| Arao, T; Mori, H; Okada, Y; Tanaka, K; Tanaka, Y; Torimoto, K | 1 |
| Assael, BM; Ballmann, M; Hebestreit, A; Holl, RW; Hubert, D; Naehrlich, L; Nickolay, T; Prinz, N; Staab, D | 1 |
| Bao, Z; Du, L; Han, F; Li, W; Lu, Q; Lv, D; Shang, Z; Wang, T; Yin, X; Zhou, X; Zhu, J | 1 |
| Aoki, S; Atsumi, T; Cho, KY; Kurihara, Y; Manda, N; Miyoshi, H; Nakamura, A; Nomoto, H; Omori, K; Ono, K; Takase, T | 1 |
| Fang, FS; Gong, YP; Li, CL; Wang, LC; Yang, G | 1 |
| Harsch, IA; Kaestner, RH; Konturek, PC | 1 |
| Huang, HK; Yeh, JI | 1 |
| Bao, Z; Chen, C; Jin, Y; Li, W; Lu, Q; Lv, D; Wang, T; Wang, X; Yin, D; Yin, X; Zhao, F; Zhao, Y; Zhou, X | 1 |
| Hakoshima, Y; Hiraishi, C; Katsuyama, H; Yanai, H | 1 |
| Huang, Q; Peng, Y; Wang, Y; Zhao, L | 1 |
| Bailey, T | 1 |
| Gao, X; Guo, H; Li, W; Lu, Q; Lv, DM; Song, JF; Wang, T; Wang, Y; Yin, XX; Zhang, F | 1 |
| Balakrishnan, P; Bass, E; Bennett, WL; Bolen, S; Clark, JM; Gribble, MO; Kao, WH; Maruthur, NM; Sahu, A; Wilson, LM | 1 |
| Fang, FS; Gong, YP; Huang, W; Li, CL; Li, J; Li, L; Tian, H; Wang, LC | 1 |
| Bardelli, M; Cantarini, L; Galeazzi, M; Rigante, D; Vitale, A | 1 |
| Liao, Y; Liu, LY; Liu, W; Ma, J; Tao, T; Wu, PH | 1 |
| Deng, H; Qin, S; Tang, W; Yin, J; Zeng, L; Zhou, B | 1 |
| Aoki, K; Kamiko, K; Kamiyama, H; Nakajima, S; Shinoda, K; Taguri, M; Terauchi, Y | 2 |
| Cui, YW; Guo, H; Li, W; Lu, Q; Lv, DM; Song, JF; Wang, DD; Wang, T; Wang, Y; Yin, XX; Zhang, F; Zhou, XY; Zhu, J | 1 |
| Andersson, C; Fosbøl, EL; Gislason, G; Køber, L; Mogensen, UM; Scheller, NM; Schramm, TK; Torp-Pedersen, C; Vaag, A | 1 |
| Constans, T; Malherbe, C; Mennecart, M; Mondon, K | 1 |
| Meillet, L | 1 |
| Abdelmoneim, AS; Huang, Y; Light, P; Qiu, W; Simpson, SH | 1 |
| Chen, M; Hu, C; Jia, W | 1 |
| George, TM; Jennings, AS; Jennings, JS; Lovett, AJ | 1 |
| DeFronzo, RA; Ferrannini, E | 1 |
| Bao, Y; Chen, M; Hu, C; Jia, W; Jiang, F; Peng, D; Wang, J; Wang, S; Wang, T; Yan, J; Zhang, R | 1 |
| Hanafusa, T; Hotta, N; Ioriya, K; Kageyama, S; Kaku, K; Kawamori, R | 1 |
| Hirose, T; Kumashiro, N; Mori, Y; Nagasawa, K; Nishimura, A; Okubo, M; Uchino, H; Usui, S; Yamato, A; Yasuda, D | 1 |
| Artuso, R; Barni, F; Braccesi, G; Casalini, E; Giglio, S; Guasti, M; Lenzi, L; Piccini, B; Toni, S | 1 |
| Adelusi, TI; Bao, Z; Li, W; Lu, Q; Lv, D; Shang, Z; Song, J; Sun, J; Wang, T; Wang, Y; Yin, X; Zhou, X; Zhu, J | 1 |
| Chang, CH; Chuang, LM; Dong, YH; Hwang, JS; Lee, YC; Lin, JW; Wu, LC | 1 |
| Amin, MM; Arbid, MS | 1 |
| Bilker, WB; Brensinger, CM; Chiang, C; Han, X; Hennessy, S; Leonard, CE; Li, L | 1 |
| Bi, Y; Engel, SS; Ji, L; Ji, Q; Jia, W; Lu, J; Mao, A; Mu, Y; Ran, X; Weng, J; Xu, W; Yang, W; Yao, B; Zeng, L; Zhao, B; Zhao, J; Zhou, Z; Zhu, D | 1 |
| Bao, YQ; He, YY; Hu, C; Jia, WP; Lu, JX; Shao, XY; Wang, CR; Xiang, KS; Zhang, R | 1 |
| Arnqvist, HJ; Chisalita, SI; Eson Jennersjö, P; Lindström, T; Olsson, AG; Paulsson, JF; Westermark, GT | 1 |
| Kalliokoski, A; Neuvonen, M; Neuvonen, PJ; Niemi, M | 1 |
| Bakiner, O; Bozkirli, E; Demirag, NG; Ertorer, ME; Tutuncu, NB | 1 |
| Li, C; Wang, L; Wang, S; Xia, J; Zhang, G | 1 |
| Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Maffioli, P; Mereu, R; Palumbo, I; Randazzo, S; Salvadeo, SA | 1 |
| Duran, C; Ercan, I; Ersoy, C; Erturk, E; Guclu, M; Imamoglu, S; Kiyici, S; Selimoglu, H; Tuncel, E | 1 |
| Cornelius, V; Kasliwal, R; Shakir, SA; Vlckova, V; Wilton, L | 1 |
| Lewin, A; Lyness, W; Raskin, P; Reinhardt, R | 2 |
| Jankovec, Z; Lacigova, S | 1 |
| Antic, S; Dimic, D; Radenkovic, S; Velojic Golubovic, M | 1 |
| Davis, SN | 1 |
| Bao, Y; Jia, W; Qiu, Y; Su, M; Wang, X; Zhao, T | 1 |
| Frandsen, M; Hansen, BV; Lund, SS; Nielsen, BB; Parving, HH; Pedersen, O; Tarnow, L; Vaag, AA | 1 |
| Chen, X; Gong, ZC; Huang, Q; Liu, ZQ; Ren, HY; Sheng, FF; Wu, J; Xu, XJ; Yin, JY; Yu, M; Zhou, HH | 1 |
| Cheng, H; Fu, Z; Li, Y; Ran, J; Shen, J; Wang, M; Xu, L; Yan, L; Zhang, Y | 1 |
| Möhlig, M; Otto, B; Pfeiffer, AF; Pivovarova, O; Rudovich, N; Spranger, J; Weickert, MO | 1 |
| Longo, R | 1 |
| Bao, YQ; Hu, C; Jia, WP; Lu, JY; Qin, W; Wang, CR; Xiang, KS; Yu, WH; Zhang, R | 1 |
| Chu, YM; Hsia, TL; Hsiao, FC; Hsieh, AT; Lee, LH; Lin, JD; Pei, C; Pei, D; Wang, K; Wu, CZ | 1 |
| Dai, XP; Dong, M; Huang, Q; Huang, X; Liu, ZQ; Pei, Q; Yin, JY; Yu, M; Zhou, HH; Zhou, ZG | 1 |
| Chen, X; Dai, XP; Deng, CS; Gong, ZC; Huang, Q; Liu, ZQ; Wu, J; Yin, JY; Yu, M; Zhou, HH | 1 |
| Jain, S; Saraf, S | 1 |
| Meneilly, GS | 1 |
| Barto, R; Engelen, L; Ferreira, I; Gram, J; Lund, SS; Parving, HH; Pedersen, O; Schalkwijk, CG; Stehouwer, CD; Tarnow, L; Teerlink, T; Vaag, AA; Winther, K | 1 |
| Bao, Y; Hu, C; Jia, W; Jiang, F; Lu, J; Qin, W; Tang, S; Wang, C; Xiang, K; Yu, W; Zhang, R | 1 |
| Bu, P; Lei, MX; Liao, EY; Luo, J; Mo, ZH; Xie, YH; Zhang, H | 1 |
| Blanco, H; Góõmez, MP; Laguna, JJ; Rojas, P; Sánchez, L; Santos, A | 1 |
| Dai, XP; Dong, M; Lei, GH; Liu, YZ; Liu, ZQ; Lu, HB; Pei, Q; Qu, J; Sheng, FF; Wu, J; Xu, XJ; Zhou, HH | 1 |
| Buysschaert, M; de la Tribonnière, X; Hermans, MP; Oriot, P; Selvais, P | 1 |
| Bu, R; Liu, J; Ning, G; Su, Q; Wang, W | 1 |
| Bain, SC; Bodvarsdottir, TB; Bracken, RM; Deacon, CF; Dunseath, G; Holst, JJ; Lowe, GD; Luzio, S; Prior, SL; Rumley, A; Stephens, JW; Wareham, K | 1 |
| Abdelmoneim, AS; Brocks, DR; Hasenbank, SE; Light, PE; Seubert, JM; Simpson, SH | 1 |
| Scott, LJ | 1 |
| Dai, XP; Dong, M; Gong, ZC; Huang, Q; Lei, GH; Liu, ZQ; Lu, HB; Pei, Q; Qu, J; Shen, J; Xu, XJ; Yin, JY; Zhou, BT; Zhou, G; Zhou, HH | 1 |
| Böhm, F; Jarnert, C; Kalani, M; Rydén, L | 1 |
| Lei, MX; Liu, ZQ; Nie, SD; Se, YM; Sun, ZX; Wang, S; Wu, J; Zeng, XM | 1 |
| Khamaisi, M | 1 |
| Dai, XP; Gong, ZC; Guo, Y; Huang, Q; Jiang, TJ; Lei, MX; Liu, ZQ; Yin, JY; Zhou, HH | 1 |
| Bao, YQ; Hu, C; Jia, WP; Jiang, F; Li, Q; Lu, JY; Tang, SS; Wang, CR; Xiang, KS; Yu, WH; Zhang, R | 1 |
| Alvarez-Avellán, L; Blanes-Castañer, V; del Pozo-Fernández, C; Gisbert-Sellés, C; López-Menchero, R; Pardo-Ruiz, C; Sánchez-Botella, C; Sánchez-Jodar, C | 1 |
| Amato, S; Baiocco, E; Curione, M; Di Bona, S; Gatti, A; Mandosi, E; Morano, S; Rossetti, M; Salvatore, S; Tarquini, G; Turinese, I; Varrenti, M | 1 |
| Favarato, D; Garzillo, CL; Girardi, P; Hueb, W; Kalil Filho, R; Lima, EG; Rahmi, RM; Ramires, JA; Rezende, PC; Strunz, CM; Takiuti, M; Uchida, AH | 1 |
| Cozma, LS; Dunseath, GJ; Langendorg, KW; Luzio, SD; Owens, DR; Pieber, T | 1 |
| Mafauzy, M | 1 |
| Furlong, NJ; Hardy, KJ; Hulme, SA; O'Brien, SV | 2 |
| Davies, MJ | 1 |
| Kaku, K; Matsuda, M | 1 |
| Göke, B; Parhofer, KG | 1 |
| Dakovska, L; Kirilov, G; Koev, D; Tankova, T | 1 |
| Hasslacher, C | 1 |
| Pørksen, N | 1 |
| Cozma, LS; Luzio, SD; Owens, DR | 1 |
| Vergès, B | 1 |
| Moses, R | 5 |
| Ciccarelli, L; Crescenzi, G; Derosa, G; Fogari, R; Mugellini, A | 2 |
| Bech, P; Gomis, R; Moses, R | 1 |
| Hale, PM; Hollander, P; Khutoryansky, N; Klaff, L; McGill, J; Raskin, P; South, SA | 1 |
| Bell, CF; Botteman, MF; Braunstein, SN; Devine, ST; Ramsdell, JW; Stephens, JM | 1 |
| Nicklasson, L; Stockl, K; Vanderplas, AM | 1 |
| Fragoulopoulos, E; Karabina, SP; Katsilambros, N; Kitsou, E; Kolia, M; Kyriaki, D; Perea, D; Sala, C; Tambaki, AP; Tentolouris, N; Tselepis, AD | 1 |
| Blicklé, JF | 1 |
| Yoshida, T; Yoshikawa, T; Yoshioka, K | 1 |
| Baron, MA | 1 |
| Gooch, B; Greco, S; Hale, PM; Hassman, DR; Jain, R; Jovanovic, L; Khutoryansky, N | 1 |
| Haslbeck, M; Jakob, S; Kellerer, M; Linn, T | 1 |
| Abrahamson, MJ | 1 |
| Barbieri, M; Barone, M; Grella, R; Paolisso, G; Passariello, N; Rizzo, MR | 1 |
| Birkeland, KI; Eriksson, J; Hreidarsson, AB; Kjellström, T; Kølendorf, K | 1 |
| Cappleman, JM; Hale, PM; Kaye, W; Khutoryansky, N; McGill, J; Raskin, P; Saad, MF | 1 |
| Figgitt, DP; Plosker, GL | 1 |
| Brazinsky, SA; Farrell, J; Hale, PM; Hassman, DR; Khutoryansky, N; Madder, RD; Rosenstock, J | 1 |
| Esposito, K; Giugliano, D; Marfella, R; Nappo, F | 1 |
| Leyck Dieken, MG; Pfeiffer, AF; Rochlitz, H; Rudovich, NN | 1 |
| Gall, MA; Lammert, M; Minshall, ME; Nicklasson, L; Palmer, AJ; Roze, S; Spinas, GA; Valentine, WJ | 1 |
| Hofmann, U; Paulwitz, O; Rosak, C | 1 |
| Banerji, MA; Crouse, RJ; Feinglos, MN; Goff, DC; Herrington, DM; Jovanovic, L; Lipkin, EW; Pettitt, DJ; Probstfield, JL; Reboussin, DM; Steffes, M; Summerson, J; Williamson, J | 1 |
| Akbas, SH; Avci, B; Balci, MK; Sari, R | 1 |
| Garon, J; Gerstein, HC; Joyce, C; Rolfe, A; Walter, CM | 1 |
| Dumitrescu, D; Guja, C; Ioacără, S; Ionescu-Tîrgovişte, C; Tomescu, I | 1 |
| Carrascosa, M; Fernández-Ayala, M; Hernández, JL; Nan, DN | 1 |
| Blackburn, GL | 1 |
| Caumo, A; Cobelli, C; Singhal, P; Taylor, R | 1 |
| Abbatecola, AM; Grella, R; Manzella, D; Paolisso, G | 1 |
| Adamson, U; Landstedt-Hallin, L; Lins, PE; Nybäck-Nakell, A; von Heijne, M | 1 |
| Abrams, Z; Lieberman, N; Shapiro, MS | 1 |
| Andrade, RJ; Borrás, J; López-García, F; Lucena, MI; Ruiz, JA; Salazar, VR; Sales, J; Verdú, C | 1 |
| Li, JW; Tian, HM; Wang, JN; Yu, HL; Zhang, XX; Zhao, GZ | 1 |
| Cozma, LS; Dunseath, GJ; Luzio, SD; Owens, DR; Underwood, PM | 1 |
| Maaravi, Y; Stessman, J | 1 |
| Malaisse, WJ | 2 |
| Panelo, A; Wing, JR | 1 |
| Barbieri, M; Grella, R; Paolisso, G; Passariello, N; Rizzo, MR | 1 |
| Damsbo, P; Gall, MA; Hollingdal, M; Juhl, CB; Pincus, S; Pørksen, N; Schmitz, O; Sturis, J; Veldhuis, JD | 1 |
| Jacobson-Dickman, E; Levitsky, L | 1 |
| Hjemdahl, P; Ostenson, CG; Wallén, NH; Yngen, M | 1 |
| Anwar, A; Azmi, KN; Hamidon, BB; Khalid, BA | 1 |
| Marshall, V; Shakir, S; Wilton, L | 1 |
| Bayram, F; Cesur, M; Corapcioglu, D; Emral, R; Gonen, S; Gursoy, A; Kamel, N; Ozduman, M; Tonyukuk, V; Uysal, AR; Yilmaz, AE | 1 |
| Fedele, V; Fioravanti, M; Leotta, C; Paolisso, G; Papa, G; Purrello, F; Rizzo, MR; Solerte, SB | 1 |
| Ciampa, F; Colatrella, A; Fallucca, F; Napoli, A | 1 |
| Betti, RT; Ferreira, BM; Gersh, BJ; Hueb, W; Lopes, N; Moffa, PJ; Ramires, JA; Uchida, AH; Wajchenberg, BL | 1 |
| Diaz-Garcia, C; Martin-Cortes, A; Mollar-Puchades, MA; Perez-Calvo, A | 1 |
| Cetinkalp, S; Erdogan, M; Karadeniz, M; Ozbek, M; Ozgen, AG; Saygili, F; Tuzun, M; Yilmaz, C | 1 |
| Grill, V; Kollind, M; Qvigstad, E; Radtke, M | 1 |
| Frandsen, M; Lund, SS; Parving, HH; Pedersen, O; Schalkwijk, CG; Smidt, UM; Stehouwer, CD; Tarnow, L; Vaag, A | 1 |
| Davies, MJ; Howe, J; Jarvis, J; Johnston, V; Kitchener, DL; Lawrence, IG; McNally, PG; Skinner, TC; Thaware, PK; Tringham, JR | 1 |
| Black, C; Donnelly, P; McIntyre, L; Royle, PL; Shepherd, JP; Thomas, S | 1 |
| Krentz, AJ | 1 |
| Huang, L; Li, J; Li, Q; Li, Y; Liang, J; Liu, Y; Luo, R; Ni, Z; Tian, H; Wang, N; Wu, T; Yu, H | 1 |
| Civera, M; Martínez, I; Merchante, A; Salvador, M; Sanz, J | 1 |
| Birkeland, KI; Johansen, OE | 1 |
| Frandsen, M; Lund, SS; Parving, HH; Pedersen, O; Smidt, UM; Tarnow, L; Vaag, AA | 1 |
| Moses, RG | 1 |
| Frandsen, M; Gram, J; Lund, SS; Parving, HH; Pedersen, O; Schalkwijk, CG; Smidt, UM; Stehouwer, CD; Tarnow, L; Teerlink, T; Vaag, AA; Winther, K | 1 |
| Khamaisi, M; Leitersdorf, E | 1 |
| Raskin, P | 1 |
| Kruseman, AC; Menheere, PP; Müller, PG; Nijst, L; Sels, JP; Wolffenbuttel, BH | 1 |
| Kikuchi, M | 1 |
| Fuhlendorff, J; Ladrière, L; Malaisse, WJ; Malaisse-Lagae, F | 1 |
| Kaku, K | 1 |
| Brand, CL; Carr, RD; Fuhlendorff, J; Kofod, H; MacKay, P; Rolin, B; Rorsman, P; Shymko, R | 1 |
| Ladrière, L; Laghmich, A; Malaisse, WJ; Malaisse-Lagae, F | 1 |
| Guanci, R; Lilley, LL | 1 |
| Balfour, JA; Faulds, D | 1 |
| Brodows, RG; Damsbo, P; Einhorn, D; Goldberg, RB; Huang, WC; Lucas, CP; Rendell, MS; Strange, P | 1 |
| Lardinois, CK | 1 |
| Owens, DR | 2 |
| Morley, JE | 1 |
| Landgraf, R; Wolffenbuttel, BH | 1 |
| Hatorp, V; Huang, WC; Strange, P | 1 |
| Clauson, P; Damsbo, P; Marbury, TC; Windfeld, K | 1 |
| Boyages, S; Carter, J; Colagiuri, S; Donnelly, T; Hopkins, H; Kidson, W; Moffitt, P; Moses, R; Slobodniuk, R | 1 |
| Huang, WC; Lebovitz, H; Marbury, T; Strange, P | 1 |
| Bilo, HJ; Landgraf, R; Müller, PG | 1 |
| DeFronzo, RA | 1 |
| Clauson, P; Damsbo, P; Hatorp, V; Marbury, TC; Müller, PG | 1 |
| Gomis, R | 1 |
| Schatz, H | 1 |
| Feinglos, MN; Hughes, AT; Luna, B | 1 |
| Smits, P; Tack, CJ | 1 |
| Wolffenbuttel, BH | 1 |
| Kuritzky, L; Quillen, DM; Samraj, GP | 1 |
| Dailey, G; Goldstein, BJ; Huang, WC; Jovanovic, L; Strange, P | 1 |
| Brillon, D; Brown, DL | 1 |
| Kolaczynski, JW | 1 |
| Larmore, SS | 1 |
| Thomsen, MK | 1 |
| Owens, D | 2 |
| Nattrass, M | 1 |
| Bailey, CJ; Nattrass, M | 1 |
| Riddle, M | 1 |
| Bayer, T; Ismail, I; Luzio, SD; Owens, DR | 1 |
| Berger, S; Jovanovic, L; Raskin, P; Ratner, R; Schwartz, S; Woo, V | 1 |
| Füchtenbusch, M; Schatz, H; Standl, E | 1 |
| Landgraf, R | 2 |
| Damsbo, P; Massi-Benedetti, M | 1 |
| Lauritzen, T; Nattrass, M | 1 |
| Garber, AJ | 1 |
| Bauer, C; Dieken, ML; Frank, M; Landgraf, R | 1 |
| Dedov, I; Frandsen, KB; Gomis, R; Moses, RG; Schlienger, JL | 1 |
| Blackburn, G | 1 |
| Kock, M | 1 |
| Quast, U | 1 |
| Abbasi, I; Hasslacher, C; Hatorp, V; Sattler, K; Schumacher, S; Sieber, J; Weise, D | 1 |
| Laws, A | 1 |
| Goldberg, RB; Strange, P | 1 |
| Dunning, BE; Foley, JE; Pratley, RE | 1 |
| Dejgaard, A; Kilhovd, B; Lager, I; Madsbad, S; Mustajoki, P | 1 |
| Boccuzzi, SJ; Fox, J; Kim, J; Shah, AB; Sung, JC; Wogen, J | 1 |
| Goldberg, RB; Graf, RJ; Huang, WC; Marbury, TC; Polvino, W; Schwartz, SL; Strange, P; Weston, I | 1 |
| Schade, DS | 1 |
| Grodsky, GM | 1 |
| De Leeuw, IH; Van Acker, KL; Van Gaal, LF | 1 |
| Scheen, AJ | 1 |
| Rutten, GE | 1 |
| Calvo Romero, JM; Lima Rodríguez, EM | 1 |
| Aller, R; Cuellar, L; de Luis, DA; Izaola, O; Ovalle, H; Romero, E; Terroba, C | 1 |
| Culy, CR; Jarvis, B | 1 |
| Dornhorst, A | 1 |
| Inzucchi, SE | 1 |
| Andersen, PH; Jønler, M; Lund, S; Pørksen, N; Schmitz, O | 1 |
| Nelson, G | 1 |
| Fossler, MJ; Haidar, SH; Hussain, AS; Johnson, SB | 1 |
| Kuritzky, L; Quillen, DM | 1 |
| Ahmann, AJ; Riddle, MC | 1 |
| Hatorp, V | 1 |
63 review(s) available for repaglinide and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2.
Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Evaluation, Preclinical; Glucose; Glucosides; Humans; Hypoglycemic Agents; Kidney; Sodium-Glucose Transporter 2 Inhibitors | 2009 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Metformin; Myocardial Infarction; Piperidines; Quality of Life; Randomized Controlled Trials as Topic; Stroke; Sulfonylurea Compounds | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Pioglitazone; Piperidines; Placebos; Randomized Controlled Trials as Topic; Risk | 2020 |
Effect of the treatment of Type 2 diabetes mellitus on the development of cognitive impairment and dementia.
Topics: Carbamates; Cause of Death; Cognition Disorders; Diabetes Mellitus, Type 2; Glyburide; Humans; Hypoglycemic Agents; Memory Disorders; Metformin; Piperidines; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones | 2017 |
Options for combination therapy in type 2 diabetes: comparison of the ADA/EASD position statement and AACE/ACE algorithm.
Topics: Algorithms; Carbamates; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Insulin; Liraglutide; Metformin; Peptides; Piperidines; Practice Guidelines as Topic; Receptors, Glucagon; Sulfonylurea Compounds; Thiazolidinediones; Venoms | 2013 |
The pharmacogenetics of type 2 diabetes: a systematic review.
Topics: Acarbose; Biomarkers, Pharmacological; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Pharmacogenetics; Pioglitazone; Piperidines; Polymorphism, Genetic; Prediabetic State; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2014 |
Comparison of repaglinide and metformin versus metformin alone for type 2 diabetes: a meta-analysis of randomized controlled trials.
Topics: Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Piperidines | 2014 |
Pharmacogenomics of glinides.
Topics: Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Inactivation, Metabolic; Insulin; Insulin Secretion; Insulin-Secreting Cells; Isoindoles; KATP Channels; Nateglinide; Pharmacogenetics; Phenylalanine; Piperidines | 2015 |
Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes.
Topics: Carbamates; Clinical Trials as Topic; Coronary Artery Disease; Cyclohexanes; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide-1 Receptor; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Insulin; Metformin; Nateglinide; Phenylalanine; Piperidines; Sodium-Glucose Transport Proteins; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome | 2015 |
Drugs for type 2 diabetes.
Topics: alpha-Galactosidase; Biguanides; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Combinations; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Nateglinide; Phenylalanine; Piperidines; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles | 2008 |
Nateglinide versus repaglinide for type 2 diabetes mellitus in China.
Topics: Carbamates; China; Cyclohexanes; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Nateglinide; Phenylalanine; Piperidines | 2009 |
Advances in oral therapy for type 2 diabetes.
Topics: Acarbose; Administration, Oral; Blood Glucose; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Combinations; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Insulin-Secreting Cells; Metformin; Nateglinide; Phenylalanine; Piperidines; Randomized Controlled Trials as Topic; Thiazolidinediones; United States; Weight Gain | 2000 |
Variations in tissue selectivity amongst insulin secretagogues: a systematic review.
Topics: Animals; ATP-Binding Cassette Transporters; Carbamates; Cardiovascular Diseases; Cricetinae; Cyclohexanes; Diabetes Mellitus, Type 2; Gliclazide; Glipizide; Glyburide; Humans; Hypoglycemic Agents; Ischemic Preconditioning, Myocardial; Isoindoles; Mice; Muscle, Smooth, Vascular; Myocytes, Cardiac; Nateglinide; Phenylalanine; Piperidines; Potassium Channels, Inwardly Rectifying; Rats; Receptors, Drug; Risk Factors; Sulfonylurea Compounds; Sulfonylurea Receptors; Tolbutamide | 2012 |
Repaglinide: a review of its use in type 2 diabetes mellitus.
Topics: Carbamates; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Piperidines; Randomized Controlled Trials as Topic | 2012 |
Severe hypoglycaemia from repaglinide-brotizolam drug interaction: a case report and literature review.
Topics: Aged; Azepines; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Drug Interactions; Humans; Hypnotics and Sedatives; Hypoglycemia; Hypoglycemic Agents; Male; Piperidines; Sleep Wake Disorders | 2012 |
Insulin secretagogues.
Topics: Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hyperglycemia; Hyperinsulinism; Hypoglycemic Agents; Insulin; Insulin Secretion; Islets of Langerhans; Nateglinide; Phenylalanine; Piperidines; Postprandial Period; Sulfonylurea Compounds; United Kingdom | 2002 |
[Repaglinide (NN-623)].
Topics: Adenosine Triphosphate; Administration, Oral; Calcium Channels; Carbamates; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Islets of Langerhans; Piperidines; Potassium Channels | 2002 |
Early changes in beta-cell function and insulin pulsatility as predictors for type 2 diabetes.
Topics: Carbamates; Circadian Rhythm; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Islets of Langerhans; Pancreas; Piperidines; Predictive Value of Tests; Pulsatile Flow | 2002 |
Early-phase prandial insulin secretion: its role in the pathogenesis of type 2 diabetes mellitus and its modulation by repaglinide.
Topics: Area Under Curve; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Glucose; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Kinetics; Liver; Piperidines | 2002 |
The impact of prandial glucose regulation in practice.
Topics: Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Patient Compliance; Piperidines; Postprandial Period; Quality of Life | 2002 |
Repaglinide in combination therapy.
Topics: Carbamates; Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Metformin; Pioglitazone; Piperidines; Postprandial Period; Rosiglitazone; Thiazoles; Thiazolidinediones; Treatment Outcome; Troglitazone | 2002 |
[symbol: see text] Nateglinide and [symbol: see text] repaglinide for type 2 diabetes?
Topics: Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Humans; Hypoglycemic Agents; Nateglinide; Phenylalanine; Piperidines; Randomized Controlled Trials as Topic; Treatment Outcome | 2003 |
[Continuation 50. Type 2 diabetes: possibilities and limitations of pharmacological therapy].
Topics: 1-Deoxynojirimycin; Acarbose; Aged; Blood Glucose; Carbamates; Contraindications; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme Inhibitors; Fasting; Follow-Up Studies; Germany; Glucosamine; Glyburide; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemia; Hypoglycemic Agents; Imino Pyranoses; Insulin; Metformin; Middle Aged; Nateglinide; Obesity; Patient Compliance; Phenylalanine; Pioglitazone; Piperidines; Practice Guidelines as Topic; Risk Factors; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Time Factors | 2003 |
Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Topics: Administration, Oral; Carbamates; Clinical Trials as Topic; Cost of Illness; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Interactions; Economics, Pharmaceutical; Humans; Hypoglycemic Agents; Piperidines; Quality of Life; Randomized Controlled Trials as Topic | 2004 |
Pharmacology of the meglitinide analogs: new treatment options for type 2 diabetes mellitus.
Topics: Animals; Benzamides; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Nateglinide; Phenylalanine; Piperidines | 2003 |
Meglitinide analogues for type 2 diabetes mellitus.
Topics: Benzamides; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Nateglinide; Phenylalanine; Piperidines; Randomized Controlled Trials as Topic | 2007 |
New oral agents for type 2 diabetes.
Topics: Acarbose; Carbamates; Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Piperidines; Pyrazoles; Rimonabant; Thiazolidinediones; Troglitazone | 2007 |
Defining the role of repaglinide in the management of type 2 diabetes mellitus: a review.
Topics: Carbamates; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug-Related Side Effects and Adverse Reactions; Humans; Hypoglycemic Agents; Piperidines | 2007 |
Oral combination therapy: repaglinide plus metformin for treatment of type 2 diabetes.
Topics: Administration, Oral; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Metformin; Piperidines; Treatment Outcome; Weight Gain | 2008 |
Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A4166.
Topics: Administration, Oral; Biological Availability; Blood Glucose; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Glyburide; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Intestinal Absorption; Molecular Structure; Nateglinide; Phenylalanine; Piperidines; Reference Values; Stereoisomerism | 1996 |
[Repaglinide (NN-623)].
Topics: Animals; Blood Glucose; Carbamates; Clinical Trials, Phase II as Topic; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Islets of Langerhans; Piperidines; Protein Precursors | 1997 |
Repaglinide.
Topics: Animals; Carbamates; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glyburide; Humans; Hypoglycemic Agents; Islets of Langerhans; Piperidines; Randomized Controlled Trials as Topic; Stereoisomerism | 1998 |
Type 2 diabetes: glycemic targets and oral therapies for older patients.
Topics: 1-Deoxynojirimycin; Acarbose; Age Factors; Aged; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Glucosamine; Humans; Hypoglycemic Agents; Imino Pyranoses; Metformin; Piperidines; Sulfonylurea Compounds; Trisaccharides | 1998 |
Repaglinide--prandial glucose regulator: a new class of oral antidiabetic drugs.
Topics: Administration, Oral; Animals; Blood Glucose; Carbamates; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Eating; Fasting; Humans; Hypoglycemic Agents; Metabolic Clearance Rate; Piperidines; Postprandial Period | 1998 |
The elderly Type 2 diabetic patient: special considerations.
Topics: Aged; Amyloid; Blood Glucose; Carbamates; Cognition Disorders; Depression; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Islet Amyloid Polypeptide; Male; Piperidines | 1998 |
Repaglinide, a new oral antidiabetic agent: a review of recent preclinical studies.
Topics: Administration, Oral; Animals; Carbamates; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Piperidines; Rats | 1999 |
Repaglinide: a new short-acting insulinotropic agent for the treatment of type 2 diabetes.
Topics: Carbamates; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Piperidines | 1999 |
Pharmacologic therapy for type 2 diabetes mellitus.
Topics: Acarbose; Administration, Oral; Algorithms; Carbamates; Chromans; Diabetes Mellitus, Type 2; Evidence-Based Medicine; Humans; Hypoglycemic Agents; Insulin; Metformin; Piperidines; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Trisaccharides; Troglitazone | 1999 |
Repaglinide as monotherapy in Type 2 diabetes.
Topics: Blood Glucose; Carbamates; Controlled Clinical Trials as Topic; Diabetes Mellitus, Type 2; Food; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Piperidines | 1999 |
Preclinical and clinical studies on safety and tolerability of repaglinide.
Topics: Aged; Animals; Carbamates; Diabetes Mellitus, Type 2; Humans; Hypoglycemia; Hypoglycemic Agents; Piperidines; Randomized Controlled Trials as Topic | 1999 |
The use of insulin secretagogues in the treatment of type 2 diabetes.
Topics: Acarbose; Carbamates; Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Metformin; Peptide Fragments; Piperidines; Protein Precursors; Risk Factors; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
New drugs for diabetes.
Topics: Carbamates; Chromans; Cyclohexanes; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Nateglinide; Phenylalanine; Piperidines; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
Repaglinide--a new compound for the treatment of patients with type 2 diabetes.
Topics: Administration, Oral; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Feeding Behavior; Humans; Hypoglycemia; Hypoglycemic Agents; Intestinal Absorption; Metabolic Clearance Rate; Piperidines | 1999 |
New directions in type 2 diabetes mellitus: an update of current oral antidiabetic therapy.
Topics: Carbamates; Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Piperidines; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
New agents for Type 2 diabetes.
Topics: Anti-Obesity Agents; Carbamates; Chromans; Diabetes Mellitus, Type 2; Drug Design; Humans; Hypoglycemic Agents; Insulin Resistance; Piperidines; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
Combining sulfonylureas and other oral agents.
Topics: Acarbose; Administration, Oral; Carbamates; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Glyburide; Humans; Hypoglycemic Agents; Metformin; Piperidines; Sulfonylurea Compounds | 2000 |
Clinical efficacy of new thiazolidinediones and glinides in the treatment of type 2 diabetes mellitus.
Topics: Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Nateglinide; Phenylalanine; Pioglitazone; Piperidines; Rosiglitazone; Thiazoles; Thiazolidinediones | 2000 |
Pharmacology and clinical experience with repaglinide.
Topics: Animals; Carbamates; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Eating; Humans; Hypoglycemic Agents; Piperidines | 2000 |
Review of prandial glucose regulation with repaglinide: a solution to the problem of hypoglycaemia in the treatment of Type 2 diabetes?
Topics: Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Eating; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Patient Compliance; Piperidines; Risk Factors; Sulfonylurea Compounds; Time Factors | 2000 |
The importance of early insulin secretion and its impact on glycaemic regulation.
Topics: Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Eating; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Piperidines; Time Factors | 2000 |
Meglitinide analogues in the treatment of type 2 diabetes mellitus.
Topics: Benzamides; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Glyburide; Humans; Hypoglycemic Agents; Molecular Structure; Nateglinide; Phenylalanine; Piperidines | 2000 |
The role of prandial glucose regulation with repaglinide in addressing the problem of hypoglycemia in the treatment of type 2 diabetes.
Topics: Carbamates; Diabetes Mellitus, Type 2; Humans; Hypoglycemia; Hypoglycemic Agents; Patient Compliance; Piperidines; Postprandial Period; Randomized Controlled Trials as Topic | 2001 |
Combination therapy in type 2 diabetes: the role of repaglinide.
Topics: Carbamates; Chromans; Diabetes Mellitus, Type 2; Drug Synergism; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin, Isophane; Metformin; Piperidines; Thiazoles; Thiazolidinediones; Troglitazone | 2001 |
A review of clinical experience with the prandial glucose regulator, repaglinide, in the treatment of type 2 diabetes.
Topics: Blood Glucose; Carbamates; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Piperidines; Postprandial Period | 2000 |
Rapid acting insulinotropic agents: restoration of early insulin secretion as a physiologic approach to improve glucose control.
Topics: Animals; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Glucose; Guanidines; Humans; Hypoglycemic Agents; Indoles; Insulin; Insulin Secretion; Isoindoles; Nateglinide; Phenylalanine; Piperidines | 2001 |
[Repaglinide, potentially a therapeutic improvement for diabetes mellitus type 2].
Topics: Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glyburide; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Metformin; Piperidines; Therapeutic Equivalency | 2001 |
[Objectives and therapeutic strategy in type 2 diabetes mellitus].
Topics: Carbamates; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Piperidines; Thiazoles | 2001 |
Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus.
Topics: Administration, Oral; Adult; Aged; Aging; Animals; Biological Availability; Blood Glucose; Carbamates; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Interactions; Glycated Hemoglobin; Half-Life; Humans; Hypoglycemic Agents; Intestinal Absorption; Metabolic Clearance Rate; Piperidines | 2001 |
Insulinotropic meglitinide analogues.
Topics: Adult; Animals; Benzamides; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Nateglinide; Phenylalanine; Piperidines; Rats | 2001 |
Oral antihyperglycemic therapy for type 2 diabetes: scientific review.
Topics: Administration, Oral; Biguanides; Blood Glucose; Carbamates; Chromans; Diabetes Mellitus, Type 2; Diet; Drug Therapy, Combination; Enzyme Inhibitors; Exercise; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Metformin; Piperidines; Randomized Controlled Trials as Topic; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Troglitazone | 2002 |
Type 2 diabetes management: a comprehensive clinical review of oral medications.
Topics: Benzamides; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Metformin; Piperidines; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones | 2002 |
Current oral agents for type 2 diabetes. Many options, but which to choose when?
Topics: Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Monitoring; Drug Therapy, Combination; Glycoside Hydrolases; Humans; Hypoglycemic Agents; Metformin; Nateglinide; Phenylalanine; Piperidines; Receptors, Cytoplasmic and Nuclear; Sulfonylurea Compounds; Transcription Factors | 2002 |
Clinical pharmacokinetics and pharmacodynamics of repaglinide.
Topics: Adult; Aged; Blood Glucose; Carbamates; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Hypoglycemic Agents; Liver Diseases; Male; Piperidines; Renal Insufficiency; Rifampin | 2002 |
100 trial(s) available for repaglinide and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Comparison of the Efficacy of Repaglinide Versus the Combination of Mitiglinide and Voglibose on Glycemic Variability in Japanese Patients with Type 2 Diabetes.
Topics: Blood Glucose; Blood Glucose Self-Monitoring; Carbamates; Cross-Over Studies; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Inositol; Isoindoles; Japan; Piperidines | 2020 |
A time to revisit the two oldest prandial anti-diabetes agents: acarbose and repaglinide.
Topics: Acarbose; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Piperidines; Prospective Studies | 2020 |
Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial.
Topics: Adolescent; Adult; Biomarkers; Blood Glucose; Carbamates; Child; Cystic Fibrosis; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Piperidines; Prognosis; Young Adult | 2018 |
A variant of GRK5 is associated with the therapeutic efficacy of repaglinide in Chinese Han patients with type 2 diabetes mellitus.
Topics: Asian People; Blood Glucose; Carbamates; Cytochrome P-450 CYP2C8; Diabetes Mellitus, Type 2; Female; G-Protein-Coupled Receptor Kinase 5; Genotype; Humans; Hypoglycemic Agents; Insulin; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Piperidines; Polymorphism, Genetic; Treatment Outcome | 2018 |
Reduction in glucose fluctuations in elderly patients with type 2 diabetes using repaglinide: A randomized controlled trial of repaglinide vs sulfonylurea.
Topics: Aged; Aged, 80 and over; Biomarkers; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Piperidines; Prognosis; Prospective Studies; Sulfonylurea Compounds | 2019 |
Characteristics of repaglinide and its mechanism of action on insulin secretion in patients with newly diagnosed type-2 diabetes mellitus.
Topics: Actins; Adult; Aged; Aged, 80 and over; Antigens; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Female; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Middle Aged; Piperidines; Treatment Outcome; Young Adult | 2018 |
Effects of NOS1AP rs12742393 polymorphism on repaglinide response in Chinese patients with type 2 diabetes mellitus.
Topics: Adaptor Proteins, Signal Transducing; Adult; Alleles; Asian People; Blood Glucose; Carbamates; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Gene Frequency; Genotype; Humans; Hypoglycemic Agents; Male; Middle Aged; Piperidines; Polymerase Chain Reaction; Polymorphism, Genetic; Polymorphism, Restriction Fragment Length; Prospective Studies | 2014 |
Comparison of repaglinide and metformin monotherapy as an initial therapy in Chinese patients with newly diagnosed type 2 diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Piperidines; Young Adult | 2014 |
Comparison of metformin and repaglinide monotherapy in the treatment of new onset type 2 diabetes mellitus in China.
Topics: Body Mass Index; Carbamates; China; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diet, Diabetic; Diet, Reducing; Drug Monitoring; Female; Glycated Hemoglobin; Humans; Hyperglycemia; Hyperlipidemias; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Overweight; Piperidines; Weight Loss | 2014 |
Effect of repaglinide, administered two or three times daily for 3 months, on glycaemic control in Japanese patients with type 2 diabetes mellitus.
Topics: Administration, Oral; Adult; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Follow-Up Studies; Glycated Hemoglobin; Glycemic Index; Humans; Hypoglycemic Agents; Japan; Male; Middle Aged; Piperidines; Prognosis | 2014 |
PPARD rs2016520 polymorphism affects repaglinide response in Chinese Han patients with type 2 diabetes mellitus.
Topics: Adult; Asian People; Carbamates; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Piperidines; Polymorphism, Genetic; Postprandial Period; PPAR delta; Treatment Outcome | 2015 |
Effect of Switching from Sulphonylurea to Repaglinide Twice or Three Times Daily for 4 Months on Glycemic Control in Japanese Patients with Type 2 Diabetes.
Topics: Aged; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Glycated Hemoglobin; Glycated Serum Albumin; Glycation End Products, Advanced; Humans; Hypoglycemic Agents; Japan; Male; Middle Aged; Piperidines; Serum Albumin; Sulfonylurea Compounds | 2016 |
Efficacy and safety of repaglinide added to sitagliptin in Japanese patients with type 2 diabetes: A randomized 24-week open-label clinical trial.
Topics: Aged; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Drug Substitution; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Middle Aged; Piperidines; Postprandial Period; Sitagliptin Phosphate; Treatment Outcome | 2016 |
A variation in KCNQ1 gene is associated with repaglinide efficacy on insulin resistance in Chinese Type 2 Diabetes Mellitus Patients.
Topics: Adult; Asian People; Carbamates; China; Diabetes Mellitus, Type 2; Female; Hep G2 Cells; Humans; Insulin Receptor Substrate Proteins; Insulin Resistance; KCNQ1 Potassium Channel; Male; Middle Aged; Phosphatidylinositol 3-Kinases; Piperidines; Polymorphism, Genetic; Proto-Oncogene Proteins c-akt; Signal Transduction | 2016 |
Efficacy and safety of metformin and sitagliptin based triple antihyperglycemic therapy (STRATEGY): a multicenter, randomized, controlled, non-inferiority clinical trial.
Topics: Acarbose; Adult; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Piperidines; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome | 2017 |
Differential lipid profile and hormonal response in type 2 diabetes by exogenous insulin aspart versus the insulin secretagogue repaglinide, at the same glycemic control.
Topics: Aged; Apolipoproteins; Blood Glucose; C-Peptide; Carbamates; Cholesterol; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Aspart; Insulin-Like Growth Factor Binding Protein 1; Insulin-Like Growth Factor I; Lipids; Lipoproteins; Male; Middle Aged; Piperidines; Proinsulin | 2009 |
Nateglinide versus repaglinide for type 2 diabetes mellitus in China.
Topics: Carbamates; China; Cyclohexanes; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Nateglinide; Phenylalanine; Piperidines | 2009 |
Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial.
Topics: Acarbose; Administration, Oral; Adult; Blood Glucose; Carbamates; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Piperidines; Sulfonylurea Compounds | 2009 |
The investigation of the efficacy of insulin glargine on glycemic control when combined with either repaglinide or acarbose in obese Type 2 diabetic patients.
Topics: Acarbose; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Male; Middle Aged; Obesity; Piperidines; Weight Gain | 2009 |
Twice-daily dosing of a repaglinide/metformin fixed-dose combination tablet provides glycaemic control comparable to rosiglitazone/metformin tablet.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Male; Metformin; Middle Aged; Patient Satisfaction; Piperidines; Rosiglitazone; Tablets; Thiazolidinediones; Young Adult | 2009 |
Twice-daily and three-times-daily dosing of a repaglinide/metformin fixed-dose combination tablet provide similar glycaemic control.
Topics: Adult; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Patient Satisfaction; Piperidines; Tablets; Young Adult | 2009 |
Evaluation of the repaglinide efficiency in comparison to the glimepiride in the type 2 diabetes patients poorly regulated by the metmorfine administration.
Topics: Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Piperidines; Sulfonylurea Compounds | 2009 |
Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial.
Topics: Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Aspart; Male; Metformin; Middle Aged; Patient Compliance; Piperidines; Treatment Outcome; Weight Gain | 2009 |
KCNJ11 Lys23Glu and TCF7L2 rs290487(C/T) polymorphisms affect therapeutic efficacy of repaglinide in Chinese patients with type 2 diabetes.
Topics: Adult; Alleles; Amino Acid Substitution; Asian People; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Female; Glutamic Acid; Humans; Lysine; Male; Middle Aged; Piperidines; Polymorphism, Genetic; Potassium Channels, Inwardly Rectifying; Risk Factors; TCF Transcription Factors; Transcription Factor 7-Like 2 Protein; Treatment Outcome | 2010 |
Effects of short-term therapy with different insulin secretagogues on glucose metabolism, lipid parameters and oxidative stress in newly diagnosed Type 2 Diabetes Mellitus.
Topics: Adult; Aged; Analysis of Variance; Blood Glucose; Carbamates; Chi-Square Distribution; Diabetes Mellitus, Type 2; Female; Fructosamine; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Lipid Peroxidation; Lipids; Male; Middle Aged; Oxidative Stress; Piperidines; Postprandial Period; Sulfonylurea Compounds; Treatment Outcome | 2010 |
Effect of meglitinides on postprandial ghrelin secretion pattern in type 2 diabetes mellitus.
Topics: Adult; Aged; Benzamides; Blood Glucose; Body Mass Index; C-Peptide; Carbamates; Cross-Over Studies; Diabetes Mellitus, Type 2; Eating; Feeding Behavior; Ghrelin; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Metformin; Middle Aged; Piperidines; Reference Values; Single-Blind Method | 2010 |
Comparison of insulin sensitivity, glucose sensitivity, and first phase insulin secretion in patients treated with repaglinide or gliclazide.
Topics: Adult; Blood Glucose; Blood Pressure; Body Mass Index; Carbamates; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Gliclazide; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipids; Male; Middle Aged; Piperidines; Time Factors; Treatment Outcome | 2010 |
Effect of repaglinide versus glyburide on postprandial glucose and insulin values in elderly patients with type 2 diabetes.
Topics: Aged; Area Under Curve; Blood Glucose; Carbamates; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Glyburide; Humans; Hypoglycemic Agents; Insulin; Male; Piperidines; Postprandial Period | 2011 |
Improved glycemic control induced by both metformin and repaglinide is associated with a reduction in blood levels of 3-deoxyglucosone in nonobese patients with type 2 diabetes.
Topics: Carbamates; Confidence Intervals; Deoxyglucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Piperidines | 2011 |
Effects of KCNQ1 polymorphisms on the therapeutic efficacy of oral antidiabetic drugs in Chinese patients with type 2 diabetes.
Topics: Administration, Oral; Adult; Alleles; Asian People; Blood Glucose; Carbamates; China; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Homeostasis; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; KCNQ1 Potassium Channel; Male; Middle Aged; Pharmacogenetics; Piperidines; Polymorphism, Single Nucleotide; Rosiglitazone; Thiazolidinediones | 2011 |
Effect of repaglinide and gliclazide on glycaemic control, early-phase insulin secretion and lipid profiles in.
Topics: Adult; Blood Glucose; Carbamates; Cholesterol; Diabetes Mellitus, Type 2; Fasting; Female; Gliclazide; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Middle Aged; Piperidines; Postprandial Period; Treatment Outcome; Triglycerides | 2011 |
Randomized study of repaglinide alone and in combination with metformin in Chinese subjects with type 2 diabetes naive to oral antidiabetes therapy.
Topics: Adolescent; Adult; Aged; Blood Glucose; Carbamates; China; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Piperidines; Young Adult | 2011 |
Effects of short-term therapy with glibenclamide and repaglinide on incretin hormones and oxidative damage associated with postprandial hyperglycaemia in people with type 2 diabetes mellitus.
Topics: Adult; Aged; Analysis of Variance; Biomarkers; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; E-Selectin; F2-Isoprostanes; Female; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glyburide; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Insulin; Intercellular Adhesion Molecule-1; Interleukin-6; Male; Metformin; Middle Aged; Oxidative Stress; Piperidines; Postprandial Period; Time Factors; Treatment Outcome; Wales | 2011 |
NeuroD1 A45T and PAX4 R121W polymorphisms are associated with plasma glucose level of repaglinide monotherapy in Chinese patients with type 2 diabetes.
Topics: Adult; Aged; Alleles; Asian People; Basic Helix-Loop-Helix Transcription Factors; Blood Glucose; Carbamates; Case-Control Studies; China; Diabetes Mellitus, Type 2; Female; Genotype; Homeodomain Proteins; Humans; Hypoglycemic Agents; Male; Middle Aged; Paired Box Transcription Factors; Piperidines; Polymorphism, Genetic; Polymorphism, Restriction Fragment Length | 2012 |
Strict glycaemic control improves skin microcirculation in patients with type 2 diabetes: a report from the Diabetes mellitus And Diastolic Dysfunction (DADD) study.
Topics: Administration, Oral; Aged; Biomarkers; Blood Glucose; Brachial Artery; Carbamates; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diastole; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Aspart; Insulin Glargine; Insulin, Long-Acting; Laser-Doppler Flowmetry; Male; Metformin; Microcirculation; Middle Aged; Piperidines; Prospective Studies; Regional Blood Flow; Skin; Sweden; Time Factors; Treatment Outcome; Vasodilation; Ventricular Dysfunction; Ventricular Function | 2012 |
KCNQ1 gene polymorphisms are associated with the therapeutic efficacy of repaglinide in Chinese type 2 diabetic patients.
Topics: Adult; Asian People; Carbamates; Diabetes Mellitus, Type 2; Female; Gene Frequency; Genotype; Humans; KCNQ1 Potassium Channel; Male; Middle Aged; Piperidines; Polymorphism, Genetic; Risk Factors; Treatment Outcome | 2012 |
Association of a SLC30A8 genetic variant with monotherapy of repaglinide and rosiglitazone effect in newly diagnosed type 2 diabetes patients in China.
Topics: Carbamates; Cation Transport Proteins; China; Diabetes Mellitus, Type 2; Female; Gene Frequency; Humans; Hypoglycemic Agents; Male; Middle Aged; Piperidines; Polymorphism, Single Nucleotide; Rosiglitazone; Thiazolidinediones; Zinc Transporter 8 | 2012 |
Lack of the QTc physiologic decrease during cardiac stress test in patients with type 2 diabetes treated with secretagogues.
Topics: Aged; Arrhythmias, Cardiac; Carbamates; Diabetes Mellitus, Type 2; Electrocardiography; Exercise Test; Female; Glyburide; Heart Rate; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Piperidines | 2014 |
Comparison of the effects of three insulinotropic drugs on plasma insulin levels after a standard meal.
Topics: Aged; Carbamates; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Eating; Female; Glipizide; Glyburide; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Islets of Langerhans; Male; Middle Aged; Piperidines | 2002 |
Repaglinide versus glibenclamide treatment of Type 2 diabetes during Ramadan fasting.
Topics: Biomarkers; Carbamates; Diabetes Mellitus, Type 2; Fasting; Feeding Behavior; Female; Fructosamine; Glyburide; Humans; Hypoglycemia; Hypoglycemic Agents; Islam; Malaysia; Male; Middle Aged; Piperidines; Risk Factors; Safety; Time Factors | 2002 |
Repaglinide versus metformin in combination with bedtime NPH insulin in patients with type 2 diabetes established on insulin/metformin combination therapy.
Topics: Blood Glucose; Carbamates; Creatinine; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Insulin, Isophane; Male; Metformin; Middle Aged; Piperidines; Time Factors | 2002 |
The effect of repaglinide on insulin secretion and oxidative stress in type 2 diabetic patients.
Topics: Carbamates; Diabetes Mellitus, Type 2; Female; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Middle Aged; Oxidative Stress; Piperidines; Superoxide Dismutase; Treatment Outcome | 2003 |
Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function.
Topics: Aged; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Hypoglycemic Agents; Lipids; Male; Middle Aged; Piperidines; Severity of Illness Index | 2003 |
Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors.
Topics: Blood Glucose; Blood Pressure; Carbamates; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Homocysteine; Humans; Hypoglycemic Agents; Lipoprotein(a); Male; Middle Aged; Piperidines; Plasminogen Activator Inhibitor 1; Risk Factors; Sulfonylurea Compounds; Time Factors; Treatment Outcome | 2003 |
Comparison of glycaemic control and cardiovascular risk profile in patients with type 2 diabetes during treatment with either repaglinide or metformin.
Topics: Blood Glucose; Carbamates; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin; Lipoproteins; Male; Metformin; Middle Aged; Piperidines; Prospective Studies; Risk Factors; Triglycerides | 2003 |
The effect of prandial glucose regulation with repaglinide on treatment satisfaction, wellbeing and health status in patients with pharmacotherapy naïve Type 2 diabetes: a placebo-controlled, multicentre study.
Topics: Carbamates; Diabetes Mellitus, Type 2; Double-Blind Method; Health Status; Health Status Indicators; Humans; Hypoglycemic Agents; Patient Satisfaction; Piperidines; Prospective Studies; Quality of Life; Surveys and Questionnaires; Translating | 2003 |
Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin.
Topics: Area Under Curve; Blood Glucose; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Nateglinide; Phenylalanine; Piperidines; Postprandial Period; Safety | 2003 |
Lack of effect of acute repaglinide administration on postprandial lipaemia in patients with type 2 diabetes mellitus.
Topics: Analysis of Variance; Blood Glucose; C-Peptide; Carbamates; Cholesterol; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Glycated Hemoglobin; Humans; Hyperlipidemias; Hypoglycemic Agents; Insulin; Kinetics; Piperidines; Postprandial Period; Triglycerides | 2003 |
Comparison of repaglinide vs. gliclazide in combination with bedtime NPH insulin in patients with Type 2 diabetes inadequately controlled with oral hypoglycaemic agents.
Topics: Administration, Oral; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Gliclazide; Hemoglobin A; Humans; Hypoglycemic Agents; Insulin, Isophane; Male; Metformin; Middle Aged; Patient Satisfaction; Piperidines; Surveys and Questionnaires; Weight Gain | 2003 |
Treatment of type 2 diabetes with a combination regimen of repaglinide plus pioglitazone.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Lipids; Middle Aged; Pioglitazone; Piperidines; Thiazolidinediones | 2004 |
Repaglinide is more efficient than glimepiride on insulin secretion and post-prandial glucose excursions in patients with type 2 diabetes. A short term study.
Topics: Aged; Aged, 80 and over; Blood Glucose; C-Peptide; Carbamates; Cholesterol; Diabetes Mellitus, Type 2; Female; Glucose Clamp Technique; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Islets of Langerhans; Kinetics; Male; Middle Aged; Piperidines; Postprandial Period; Sulfonylurea Compounds; Time Factors; Triglycerides | 2004 |
Dose titration of repaglinide in patients with inadequately controlled type 2 diabetes.
Topics: Adult; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Piperidines; Postprandial Period; Safety | 2004 |
Combination therapy for type 2 diabetes: repaglinide plus rosiglitazone.
Topics: Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Piperidines; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Weight Gain | 2004 |
Repaglinide versus nateglinide monotherapy: a randomized, multicenter study.
Topics: Biomarkers; Body Mass Index; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Diet, Diabetic; Exercise; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Nateglinide; Phenylalanine; Piperidines; Time Factors | 2004 |
Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus.
Topics: Adult; Aged; Biomarkers; Blood Glucose; Carbamates; Carotid Artery Diseases; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Fasting; Female; Glyburide; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Inflammation; Insulin; Lipids; Male; Middle Aged; Piperidines; Postprandial Period; Single-Blind Method; Tunica Intima; Tunica Media; Ultrasonography | 2004 |
Enhancement of early- and late-phase insulin secretion and insulin sensitivity by the combination of repaglinide and metformin in type 2 diabetes mellitus.
Topics: Adult; Aged; C-Peptide; Carbamates; Cohort Studies; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Synergism; Drug Therapy, Combination; Female; Glucose Clamp Technique; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Metformin; Middle Aged; Piperidines; Placebos; Time Factors | 2004 |
Modification of beta-cell response to different postprandial blood glucose concentrations by prandial repaglinide and combined acarbose/repaglinide application.
Topics: Acarbose; Adult; Aged; Blood Glucose; C-Peptide; Carbamates; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Food; Humans; Hypoglycemic Agents; Insulin; Islets of Langerhans; Male; Middle Aged; Piperidines; Proinsulin | 2004 |
The combination oral and nutritional treatment of late-onset diabetes mellitus (CONTROL DM) trial results.
Topics: Administration, Oral; Adult; Aged; Brachial Artery; Carbamates; Combined Modality Therapy; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Piperidines; Treatment Outcome; Vasodilation | 2004 |
The effects of diet, sulfonylurea, and Repaglinide therapy on clinical and metabolic parameters in type 2 diabetic patients during Ramadan.
Topics: 3-Hydroxybutyric Acid; Blood Glucose; Carbamates; Cholesterol, HDL; Diabetes Mellitus, Type 2; Fasting; Humans; Hypoglycemic Agents; Islam; Middle Aged; Piperidines; Postprandial Period; Sulfonylurea Compounds; Triglycerides | 2004 |
Pre-prandial vs. post-prandial capillary glucose measurements as targets for repaglinide dose titration in people with diet-treated or metformin-treated Type 2 diabetes: a randomized controlled clinical trial.
Topics: Adult; Aged; Blood Glucose; Blood Specimen Collection; Carbamates; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Monitoring; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Piperidines; Postprandial Period | 2004 |
Effect of repaglinide and gliclazide on postprandial control of endogenous glucose production.
Topics: Adult; Carbamates; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Gliclazide; Glucagon; Glucose; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Oxidation-Reduction; Piperidines; Postprandial Period | 2005 |
Repaglinide administration improves brachial reactivity in type 2 diabetic patients.
Topics: Aged; Blood Glucose; Brachial Artery; Carbamates; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endothelium, Vascular; Female; Glyburide; Humans; Hypoglycemic Agents; Male; Middle Aged; Oxidative Stress; Piperidines | 2005 |
Clinical experience with repaglinide in patients with non-insulin-dependent diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Body Weight; Carbamates; Diabetes Mellitus, Type 2; Diet; Feeding Behavior; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Piperidines; Stereoisomerism; Treatment Outcome | 2005 |
[Comparison of efficacy between nateglinide and repaglinide in treating type 2 diabetes: a randomized controlled double-blind clinical trial].
Topics: Adult; Blood Glucose; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Middle Aged; Nateglinide; Phenylalanine; Piperidines | 2005 |
Beta-cell response during a meal test: a comparative study of incremental doses of repaglinide in type 2 diabetic patients.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Carbamates; Cross-Over Studies; Diabetes Mellitus, Type 2; Eating; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Islets of Langerhans; Male; Middle Aged; Piperidines; Postprandial Period | 2005 |
Repaglinide/bedtime NPH insulin is comparable to twice-daily NPH insulin.
Topics: Adult; Blood Glucose; Body Mass Index; Carbamates; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin, Isophane; Male; Patient Dropouts; Piperidines | 2005 |
Repaglinide has more beneficial effect on cardiovascular risk factors than glimepiride: data from meal-test study.
Topics: Aged; Aged, 80 and over; Area Under Curve; Blood Glucose; Carbamates; Cardiovascular Diseases; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diet, Diabetic; Eating; Female; Humans; Hypoglycemic Agents; Insulin; Lipids; Male; Middle Aged; Piperidines; Sulfonylurea Compounds; Thiobarbituric Acid Reactive Substances | 2005 |
Repaglinide treatment amplifies first-phase insulin secretion and high-frequency pulsatile insulin release in Type 2 diabetes.
Topics: Administration, Oral; Adult; Aged; Blood Glucose; Carbamates; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Homeostasis; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Middle Aged; Piperidines; Secretory Rate | 2005 |
Meal-induced platelet activation in Type 2 diabetes mellitus: effects of treatment with repaglinide and glibenclamide.
Topics: Adenosine Diphosphate; Blood Glucose; C-Reactive Protein; Carbamates; Cross-Over Studies; Diabetes Mellitus, Type 2; Eating; Fasting; Female; Glyburide; Humans; Hypoglycemic Agents; Insulin; Intercellular Adhesion Molecule-1; Male; Middle Aged; P-Selectin; Piperidines; Platelet Activation; Platelet Function Tests; Postprandial Period; Treatment Outcome; von Willebrand Factor | 2006 |
An open label comparative study of glimepiride versus repaglinide in type 2 diabetes mellitus Muslim subjects during the month of Ramadan.
Topics: Adult; Aged; Blood Glucose; Carbamates; Ceremonial Behavior; Diabetes Mellitus, Type 2; Fasting; Female; Humans; Hypoglycemic Agents; Islam; Male; Middle Aged; Piperidines; Sulfonylurea Compounds; Time Factors; Treatment Outcome | 2006 |
Safety of type 2 diabetes treatment with repaglinide compared with glibenclamide in elderly people: A randomized, open-label, two-period, cross-over trial.
Topics: Aged; Carbamates; Cross-Over Studies; Diabetes Mellitus, Type 2; Glyburide; Humans; Piperidines | 2006 |
Effect of a hypoglycemic agent on ischemic preconditioning in patients with type 2 diabetes and stable angina pectoris.
Topics: Angina Pectoris; Carbamates; Diabetes Mellitus, Type 2; Electrocardiography; Exercise Test; Female; Humans; Hypoglycemic Agents; Ischemic Preconditioning, Myocardial; Male; Middle Aged; Piperidines; Time Factors | 2007 |
Preprandial repaglinide decreases exogenous insulin requirements and HbA1c levels in type 2 diabetic patients taking intensive insulin treatment.
Topics: Body Mass Index; Carbamates; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Piperidines | 2006 |
Twelve weeks' treatment with diazoxide without insulin supplementation in Type 2 diabetes is feasible but does not improve insulin secretion.
Topics: Carbamates; Diabetes Mellitus, Type 2; Diazoxide; Dose-Response Relationship, Drug; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Piperidines; Treatment Outcome | 2007 |
Targeting hyperglycaemia with either metformin or repaglinide in non-obese patients with type 2 diabetes: results from a randomized crossover trial.
Topics: Adiponectin; Biomarkers; Blood Glucose; Body Weight; C-Peptide; C-Reactive Protein; Carbamates; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Patient Compliance; Piperidines; Prospective Studies; Waist-Hip Ratio | 2007 |
A randomized controlled trial examining combinations of repaglinide, metformin and NPH insulin.
Topics: Adult; Aged; Aged, 80 and over; Carbamates; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin, Isophane; Male; Metformin; Middle Aged; Piperidines; Treatment Outcome; Weight Gain | 2007 |
Improvement of insulin sensitivity and beta-cell function by nateglinide and repaglinide in type 2 diabetic patients - a randomized controlled double-blind and double-dummy multicentre clinical trial.
Topics: Adult; Age of Onset; Aged; Area Under Curve; Asian People; Blood Glucose; Carbamates; China; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Humans; Insulin; Insulin Secretion; Insulin-Secreting Cells; Middle Aged; Nateglinide; Phenylalanine; Piperidines | 2007 |
Safety and efficacy of repaglinide in combination with metformin and bedtime NPH insulin as an insulin treatment regimen in type 2 diabetes.
Topics: Aged; Blood Glucose; Blood Pressure; Body Mass Index; Carbamates; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Insulin, Isophane; Male; Metformin; Middle Aged; Piperidines; Prospective Studies; Safety; Weight Gain | 2008 |
Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes.
Topics: Aged; Area Under Curve; Blood Glucose; Carbamates; Cholesterol; Cholesterol, LDL; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; Fatty Acids, Nonesterified; Female; Humans; Hypoglycemic Agents; Insulin; Lipids; Male; Metformin; Middle Aged; Piperidines; Postprandial Period; Triglycerides | 2008 |
Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Body Weight; Carbamates; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endothelium, Vascular; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Piperidines; Risk Factors; Treatment Outcome; Vasculitis | 2008 |
Effects of a new oral hypoglycaemic agent, repaglinide, on metabolic control in sulphonylurea-treated patients with NIDDM.
Topics: Aged; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Female; Fructosamine; Gliclazide; Glyburide; Glycated Hemoglobin; Hexosamines; Humans; Hypoglycemic Agents; Lipids; Male; Middle Aged; Piperidines; Tolbutamide | 1993 |
Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A4166.
Topics: Administration, Oral; Biological Availability; Blood Glucose; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Glyburide; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Intestinal Absorption; Molecular Structure; Nateglinide; Phenylalanine; Piperidines; Reference Values; Stereoisomerism | 1996 |
A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes.
Topics: Adult; Aged; Carbamates; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Piperidines | 1998 |
A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Dutch and German Repaglinide Study Group.
Topics: Adult; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Piperidines | 1999 |
A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients.
Topics: Adult; Aged; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Diet, Diabetic; Double-Blind Method; Drug Administration Schedule; Eating; Energy Intake; Fasting; Glyburide; Humans; Hypoglycemic Agents; Middle Aged; Piperidines | 1999 |
Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes.
Topics: Australia; Blood Glucose; C-Peptide; Carbamates; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fasting; Fatty Acids, Nonesterified; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Piperidines; Triglycerides | 1999 |
Repaglinide versus glyburide: a one-year comparison trial.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Carbamates; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fibrinogen; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Piperidines; Prospective Studies; Triglycerides; United States; United States Food and Drug Administration | 1999 |
A comparison of repaglinide and glibenclamide in the treatment of type 2 diabetic patients previously treated with sulphonylureas.
Topics: Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glyburide; Humans; Hypoglycemic Agents; Male; Middle Aged; Piperidines; Sulfonylurea Compounds | 1999 |
Flexible prandial glucose regulation with repaglinide in patients with type 2 diabetes.
Topics: Aged; Area Under Curve; Blood Glucose; Carbamates; Cholesterol; Diabetes Mellitus, Type 2; Eating; Female; Fructosamine; Humans; Hypoglycemic Agents; Indicators and Reagents; Male; Middle Aged; Nitroblue Tetrazolium; Piperidines; Prospective Studies; Triglycerides | 1999 |
Repaglinide in combination therapy with metformin in Type 2 diabetes.
Topics: Australia; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Piperidines | 1999 |
Repaglinide in type 2 diabetes: a 24-week, fixed-dose efficacy and safety study.
Topics: Adult; Aged; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Fasting; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Patient Dropouts; Piperidines; Time Factors; Treatment Outcome | 2000 |
Increased prandial insulin secretion after administration of a single preprandial oral dose of repaglinide in patients with type 2 diabetes.
Topics: Administration, Oral; Area Under Curve; Blood Glucose; C-Peptide; Carbamates; Cohort Studies; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Eating; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Middle Aged; Piperidines | 2000 |
Repaglinide/troglitazone combination therapy: improved glycemic control in type 2 diabetes.
Topics: Adult; Aged; Biomarkers; Blood Glucose; Carbamates; Chromans; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Piperidines; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
Flexible meal-related dosing with repaglinide facilitates glycemic control in therapy-naive type 2 diabetes.
Topics: Aged; Blood Glucose; Body Weight; Carbamates; Diabetes Mellitus, Type 2; Diet; Double-Blind Method; Fasting; Female; Food; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Piperidines; Placebos | 2001 |
Single- and multiple-dose pharmacokinetics of repaglinide in patients with type 2 diabetes and renal impairment.
Topics: Aged; Analysis of Variance; Area Under Curve; Carbamates; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Hypoglycemic Agents; Male; Metabolic Clearance Rate; Middle Aged; Piperidines; Renal Insufficiency | 2001 |
Comparison between repaglinide and glipizide in Type 2 diabetes mellitus: a 1-year multicentre study.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Carbamates; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diabetic Neuropathies; Diabetic Retinopathy; Double-Blind Method; Fasting; Female; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Piperidines | 2001 |
Pharmacokinetics, pharmacodynamics, and dose-response relationship of repaglinide in type 2 diabetes.
Topics: Adult; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Ethnicity; Fasting; Female; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Piperidines; Placebos; United States | 1999 |
Repaglinide improves blood glucose control in sulphonylurea-naive type 2 diabetes.
Topics: Area Under Curve; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Fasting; Fructosamine; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Middle Aged; Piperidines; Placebos; Postprandial Period; Time Factors | 2001 |
Optimizing insulin secretagogue therapy in patients with type 2 diabetes: a randomized double-blind study with repaglinide.
Topics: Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Double-Blind Method; Eating; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Middle Aged; Piperidines; Postprandial Period | 2002 |
Modeling the pharmacokinetics and pharmacodynamics of a unique oral hypoglycemic agent using neural networks.
Topics: Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Neural Networks, Computer; Piperidines; Predictive Value of Tests | 2002 |
98 other study(ies) available for repaglinide and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Synthesis of hydantoin analogues of (2S,3R,4S)-4-hydroxyisoleucine with insulinotropic properties.
Topics: Animals; Diabetes Mellitus, Type 2; Hydantoins; Insulin; Insulin Secretion; Isoleucine; Molecular Structure; Rats; Stereoisomerism; Structure-Activity Relationship | 2008 |
Clinical Effects of Exercise Rehabilitation Combined with Repaglinide in the Treatment of Diabetes.
Topics: Carbamates; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Piperidines; Retrospective Studies | 2022 |
In Vivo Evaluation of Nanoemulsion Formulations for Metformin and Repaglinide Alone and Combination.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Metformin; Rats | 2023 |
Hydrophilic interaction liquid chromatography-electrospray ionization mass spectrometry combined with fabric phase sorptive extraction for therapeutic drug monitoring of pioglitazone, repaglinide, and nateglinide in human plasma.
Topics: Chromatography, High Pressure Liquid; Chromatography, Liquid; Diabetes Mellitus, Type 2; Drug Monitoring; Humans; Hydrophobic and Hydrophilic Interactions; Nateglinide; Pioglitazone; Spectrometry, Mass, Electrospray Ionization | 2023 |
Acarbose versus Repaglinide in Diabetes Treatment: A New Appraisal of Two Old Rivals.
Topics: Acarbose; Adult; Aged; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Female; Humans; Hyperglycemia; Hypoglycemic Agents; Iran; Male; Middle Aged; Piperidines | 2020 |
Repaglinide and Metformin-Loaded Amberlite Resin-Based Floating Microspheres for the Effective Management of Type 2 Diabetes.
Topics: Animals; Carbamates; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Metformin; Mice; Microspheres; Piperidines; Rats; Resins, Synthetic | 2021 |
Hypoglycemia during the Concomitant Use of Repaglinide and Clopidogrel in an Elderly Patient with Type 2 Diabetes and Severe Renal Insufficiency.
Topics: Aged; Blood Glucose; Carbamates; Clopidogrel; Diabetes Mellitus, Type 2; Humans; Hypoglycemia; Hypoglycemic Agents; Piperidines; Renal Insufficiency | 2021 |
Risk of Death and Heart Failure among Patients with Type 2 Diabetes Treated by Metformin and Nonmetformin Monotherapy: A Real-World Study.
Topics: Aged; Benzamides; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycoside Hydrolase Inhibitors; Heart Failure; Hospitalization; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Mortality; Nateglinide; Piperidines; Proportional Hazards Models; Retrospective Studies; Sulfonylurea Compounds; Thiazolidinediones | 2021 |
Angiotensin-Converting Enzyme Inhibitors Used Concomitantly with Insulin Secretagogues and the Risk of Serious Hypoglycemia.
Topics: Administrative Claims, Healthcare; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Carbamates; Databases, Factual; Diabetes Mellitus, Type 2; Drug Interactions; Female; Glipizide; Glyburide; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Medicaid; Metformin; Middle Aged; Nateglinide; Pharmacoepidemiology; Piperidines; Secretagogues; Sulfonylurea Compounds; United States | 2022 |
Type 2 Diabetes Mellitus Treatment Patterns Across Europe: A Population-based Multi-database Study.
Topics: Aged; Carbamates; Databases, Factual; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Drug Utilization; Europe; Female; Humans; Hypoglycemic Agents; Incretins; Male; Metformin; Middle Aged; Piperidines; Sulfonylurea Compounds | 2017 |
The Effects of Mitiglinide and Repaglinide on Postprandial Hyperglycemia in Patients Undergoing Methylprednisolone Pulse Therapy.
Topics: Aged; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Female; Graves Ophthalmopathy; Humans; Hyperglycemia; Hypoglycemic Agents; Isoindoles; Male; Methylprednisolone; Middle Aged; Piperidines; Treatment Outcome | 2018 |
Hypoglycemic side effects of sulfonylureas and repaglinide in ageing patients - knowledge and self-management.
Topics: Aged; Aged, 80 and over; Aging; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Health Knowledge, Attitudes, Practice; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Piperidines; Self-Management; Sulfonylurea Compounds | 2018 |
Comparison of mortality and cardiovascular event risk associated with various insulin secretagogues: A nationwide real-world analysis.
Topics: Aged; Carbamates; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gliclazide; Glipizide; Glyburide; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Middle Aged; Mortality; Piperidines; Secretagogues; Sulfonylurea Compounds; Taiwan | 2019 |
A Variation in the ABCC8 Gene Is Associated with Type 2 Diabetes Mellitus and Repaglinide Efficacy in Chinese Type 2 Diabetes Mellitus Patients.
Topics: Alleles; Asian People; Carbamates; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Genotype; Humans; Hypoglycemic Agents; Male; Middle Aged; Piperidines; Polymerase Chain Reaction; Polymorphism, Genetic; Polymorphism, Restriction Fragment Length; Sulfonylurea Receptors | 2019 |
Severe thrombocytopenia due to repaglinide in a patient with type 2 diabetes.
Topics: Aged; Carbamates; Diabetes Mellitus, Type 2; Humans; Male; Piperidines; Thrombocytopenia | 2013 |
Effects of dipeptidyl peptidase-4 inhibitors in a type 2 diabetes patient with failure of glucagon-like peptide-1 receptor agonists.
Topics: Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Exenatide; Fasting; Female; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Metformin; Middle Aged; Peptides; Piperidines; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Treatment Failure; Triazoles; Venoms | 2014 |
Anakinra treatment in patients with gout and type 2 diabetes.
Topics: Aged; Aged, 80 and over; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Blood Glucose; Carbamates; Colchicine; Diabetes Mellitus, Type 2; Febuxostat; Glycated Hemoglobin; Gout; Gout Suppressants; Humans; Hyperuricemia; Hypoglycemic Agents; Insulin; Interleukin 1 Receptor Antagonist Protein; Metformin; Middle Aged; Piperidines; Treatment Outcome; Uric Acid | 2015 |
Metformin in combination with various insulin secretagogues in type 2 diabetes and associated risk of cardiovascular morbidity and mortality--a retrospective nationwide study.
Topics: Aged; Carbamates; Cardiovascular Diseases; Denmark; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Gliclazide; Glipizide; Glyburide; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Morbidity; Myocardial Infarction; Piperidines; Registries; Retrospective Studies; Risk Factors; Stroke; Sulfonylurea Compounds; Tolbutamide | 2015 |
Delayed hypoglycemia induced by repaglinide in a frail elderly adult with diabetes mellitus.
Topics: Aged, 80 and over; Carbamates; Diabetes Mellitus, Type 2; Frail Elderly; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Piperidines | 2014 |
[New medications for patients with type 2 diabetes].
Topics: Carbamates; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon-Like Peptide 1; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Incretins; Piperidines | 2014 |
Comparative cardiovascular safety of insulin secretagogues following hospitalization for ischemic heart disease among type 2 diabetes patients: a cohort study.
Topics: Aged; Aged, 80 and over; Alberta; Blue Cross Blue Shield Insurance Plans; Carbamates; Cardiovascular Diseases; Cohort Studies; Databases, Factual; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Female; Gliclazide; Glyburide; Hospitalization; Humans; Hypoglycemic Agents; Male; Myocardial Ischemia; Piperidines; Proportional Hazards Models; Retrospective Studies; Risk; Universal Health Insurance | 2015 |
Getting to goal in newly diagnosed type 2 diabetes using combination drug "subtraction therapy".
Topics: Adult; Aged; Aged, 80 and over; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Goals; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Piperidines; Thiazolidinediones; Treatment Outcome | 2015 |
Joint effects of diabetic-related genomic loci on the therapeutic efficacy of oral anti-diabetic drugs in Chinese type 2 diabetes patients.
Topics: Administration, Oral; Adult; Alleles; Asian People; Blood Glucose; Body Mass Index; Carbamates; China; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Genetic Loci; Genotype; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linear Models; Male; Middle Aged; Piperidines; Polymorphism, Single Nucleotide; Rosiglitazone; Thiazolidinediones | 2016 |
Clinical study of repaglinide efficacy and safety in type 2 diabetes mellitus patients with blood glucose levels inadequately controlled by sitagliptin.
Topics: Adult; Aged; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Piperidines; Sitagliptin Phosphate | 2016 |
Clinical and molecular characterization of a novel INS mutation identified in patients with MODY phenotype.
Topics: Adolescent; Animals; Carbamates; Child; Diabetes Mellitus, Type 2; Female; Heterozygote; High-Throughput Nucleotide Sequencing; Humans; Insulin; Insulin-Secreting Cells; Male; Mice; Mutation; Pedigree; Piperidines; Regulatory Factor X Transcription Factors | 2016 |
Comparing the risks of hospitalized heart failure associated with glinide, sulfonylurea, and acarbose use in type 2 diabetes: A nationwide study.
Topics: Acarbose; Administration, Oral; Age Factors; Aged; Carbamates; Cohort Studies; Confidence Intervals; Databases, Factual; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Heart Failure; Hospital Mortality; Hospitalization; Humans; Hypoglycemic Agents; Incidence; Male; Middle Aged; Piperidines; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Sex Factors; Sulfonylurea Compounds; Survival Rate; Taiwan | 2017 |
Estimation of ellagic acid and/or repaglinide effects on insulin signaling, oxidative stress, and inflammatory mediators of liver, pancreas, adipose tissue, and brain in insulin resistant/type 2 diabetic rats.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Biomarkers; Brain; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ellagic Acid; Hyperglycemia; Hypoglycemic Agents; Inflammation Mediators; Insulin Resistance; Intra-Abdominal Fat; Liver; Male; Neurons; Oxidative Stress; Pancreas; Piperidines; Rats, Wistar | 2017 |
Biomedical Informatics Approaches to Identifying Drug-Drug Interactions: Application to Insulin Secretagogues.
Topics: Area Under Curve; Carbamates; Cyclohexanes; Databases, Factual; Diabetes Mellitus, Type 2; Drug Interactions; Glipizide; Glyburide; Humans; Hypoglycemia; Hypoglycemic Agents; Medical Informatics; Nateglinide; Pharmacoepidemiology; Phenylalanine; Piperidines; Sulfonylurea Compounds | 2017 |
Association of KCNJ11 and ABCC8 genetic polymorphisms with response to repaglinide in Chinese diabetic patients.
Topics: ATP-Binding Cassette Transporters; Carbamates; Diabetes Mellitus, Type 2; DNA; Female; Gene Frequency; Genotype; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Piperidines; Polymorphism, Genetic; Potassium Channels, Inwardly Rectifying; Receptors, Drug; Sulfonylurea Receptors | 2008 |
The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range.
Topics: Area Under Curve; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Female; Genotype; Humans; Hypoglycemic Agents; Liver-Specific Organic Anion Transporter 1; Male; Metabolic Clearance Rate; Organic Anion Transporters; Piperidines; Polymorphism, Single Nucleotide; Young Adult | 2008 |
Repaglinide plus single-dose insulin glargine: a safe regimen for low-risk type 2 diabetic patients who insist on fasting in Ramadan.
Topics: Adult; Aged; Blood Glucose; Blood Glucose Self-Monitoring; Blood Pressure; Carbamates; Diabetes Mellitus, Type 2; Drug Administration Schedule; Fasting; Female; Fructosamine; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Islam; Male; Middle Aged; Patient Selection; Piperidines; Risk Assessment; Safety; Turkey | 2009 |
Hypoglycaemia with oral antidiabetic drugs: results from prescription-event monitoring cohorts of rosiglitazone, pioglitazone, nateglinide and repaglinide.
Topics: Administration, Oral; Adult; Adverse Drug Reaction Reporting Systems; Carbamates; Cohort Studies; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Monitoring; Drug Prescriptions; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Incidence; Male; Middle Aged; Nateglinide; Phenylalanine; Pioglitazone; Piperidines; Rosiglitazone; Sex Factors; Thiazolidinediones | 2009 |
Metformin/Repaglinide (PrandiMet) for type 2 diabetes.
Topics: Administration, Oral; Carbamates; Diabetes Mellitus, Type 2; Drug Combinations; Drug Interactions; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Piperidines; Tablets; Treatment Outcome | 2009 |
Change in glucometer settings as a cause of sudden deterioration of glycemic control in type 2 diabetes.
Topics: Blood Glucose; Blood Glucose Self-Monitoring; Carbamates; Computers; Diabetes Mellitus, Type 2; Equipment Failure; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Metformin; Middle Aged; Piperidines; Self Care; Software | 2009 |
Metabonomic variations in the drug-treated type 2 diabetes mellitus patients and healthy volunteers.
Topics: Carbamates; Diabetes Mellitus, Type 2; Gas Chromatography-Mass Spectrometry; Humans; Hypoglycemic Agents; Lactic Acid; Lysine; Metabolomics; Metformin; Piperidines; Rosiglitazone; Thiazolidinediones; Uric Acid; Valine | 2009 |
Diabetes under control: Understanding oral antidiabetic agents.
Topics: Administration, Oral; Biguanides; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Drug Therapy, Combination; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Nateglinide; Phenylalanine; Piperidines; Sulfonylurea Compounds | 2010 |
A variation in NOS1AP gene is associated with repaglinide efficacy on insulin resistance in type 2 diabetes of Chinese.
Topics: Adaptor Proteins, Signal Transducing; Carbamates; China; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Piperidines; Polymorphism, Single Nucleotide | 2010 |
IGF2BP2 variations influence repaglinide response and risk of type 2 diabetes in Chinese population.
Topics: Adult; Aged; Asian People; Carbamates; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Gene Frequency; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Piperidines; Polymorphism, Genetic; Risk Factors; RNA-Binding Proteins | 2010 |
Association analysis of SLC30A8 rs13266634 and rs16889462 polymorphisms with type 2 diabetes mellitus and repaglinide response in Chinese patients.
Topics: Adult; Aged; Base Sequence; Carbamates; Case-Control Studies; Cation Transport Proteins; China; Diabetes Mellitus, Type 2; DNA Primers; Female; Gene Frequency; Genome-Wide Association Study; Humans; Hypoglycemic Agents; Male; Middle Aged; Piperidines; Polymerase Chain Reaction; Polymorphism, Genetic; Zinc Transporter 8 | 2010 |
Repaglinide-loaded long-circulating biodegradable nanoparticles: rational approach for the management of type 2 diabetes mellitus.
Topics: Administration, Oral; Animals; Blood Glucose; Carbamates; Chemistry, Pharmaceutical; Delayed-Action Preparations; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Drug Compounding; Hypoglycemic Agents; Lactic Acid; Male; Nanoparticles; Particle Size; Piperidines; Polyethylene Glycols; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Rats, Sprague-Dawley; Solubility | 2009 |
Hypersensitivity to repaglinide.
Topics: Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Hypersensitivity; Erythema; Exanthema; Humans; Hypoglycemic Agents; Male; Middle Aged; Nateglinide; Patch Tests; Phenylalanine; Piperidines | 2011 |
NAMPT -3186C/T polymorphism affects repaglinide response in Chinese patients with Type 2 diabetes mellitus.
Topics: Adult; Aged; Alleles; Asian People; Carbamates; Cholesterol; Control Groups; Diabetes Mellitus, Type 2; Female; Genetic Predisposition to Disease; Genotype; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Nicotinamide Phosphoribosyltransferase; Piperidines; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Treatment Outcome | 2011 |
Exenatide improves weight loss insulin sensitivity and β-cell function following administration to a type 2 diabetic HIV patient on antiretroviral therapy.
Topics: Adipose Tissue; Antiretroviral Therapy, Highly Active; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; HIV Infections; Humans; Hypoglycemic Agents; Insulin Resistance; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Peptides; Piperidines; Venoms; Waist Circumference; Weight Loss | 2011 |
Effect of genetic polymorphism of UCP2-866 G/A on repaglinide response in Chinese patients with type 2 diabetes.
Topics: Adult; Aged; Alleles; Asian People; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; DNA Primers; Female; Genotype; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Ion Channels; Male; Middle Aged; Mitochondrial Proteins; Pancreatic Function Tests; Piperidines; Polymerase Chain Reaction; Uncoupling Protein 2 | 2012 |
Discrepancies among consensus documents, guidelines, clinical practice and the legal framework for the treatment of type 2 diabetes mellitus patients.
Topics: Acidosis, Lactic; Aged; Carbamates; Consensus Development Conferences as Topic; Contraindications; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Management; Drug Utilization; Endocrinology; Female; Follow-Up Studies; Glomerular Filtration Rate; Hospital Departments; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nephrology; Piperidines; Practice Guidelines as Topic; Primary Health Care; Professional Practice; Societies, Medical; Spain; Sulfonylurea Compounds | 2012 |
Effect of hypoglycemic agents on ischemic preconditioning in patients with type 2 diabetes and symptomatic coronary artery disease.
Topics: Adamantane; Aged; Carbamates; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Ischemic Preconditioning; Male; Middle Aged; Nitriles; Piperidines; Prospective Studies; Pyrrolidines; Vildagliptin | 2013 |
[Glinides and glitazones in diabetes treatment. Are they really effective?].
Topics: Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Nateglinide; Phenylalanine; Pioglitazone; Piperidines; Rosiglitazone; Thiazoles; Thiazolidinediones; Treatment Outcome | 2002 |
Economic model of first-line drug strategies to achieve recommended glycaemic control in newly diagnosed type 2 diabetes mellitus.
Topics: Carbamates; Cohort Studies; Decision Trees; Diabetes Mellitus, Type 2; Direct Service Costs; Drug Costs; Drug Therapy, Combination; Glipizide; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Managed Care Programs; Markov Chains; Metformin; Models, Economic; Piperidines; Rosiglitazone; Thiazoles; Thiazolidinediones; United States | 2003 |
A comparison of costs for four oral antidiabetic regimens within a managed care population.
Topics: Administration, Oral; Adolescent; Adult; Aged; California; Carbamates; Cohort Studies; Data Interpretation, Statistical; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glyburide; Health Care Costs; Humans; Hypoglycemic Agents; Insulin; Insurance Claim Review; Male; Managed Care Programs; Metformin; Middle Aged; Piperidines; Retrospective Studies | 2003 |
[Type 2 diabetes mellitus pathogenesis: new therapeutic managements?].
Topics: Carbamates; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Piperidines; Treatment Outcome | 2003 |
Glimepiride and serum adiponectin level in type 2 diabetic subjects: response to Nagasaka et al.
Topics: Adiponectin; Blood Glucose; Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Intercellular Signaling Peptides and Proteins; Nateglinide; Phenylalanine; Piperidines; Proteins; Sulfonylurea Compounds | 2003 |
Comparison of repaglinide and nateglinide in combination with metformin: response to Raskin et al.
Topics: Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Nateglinide; Phenylalanine; Piperidines | 2003 |
Optimal glycemic control in type 2 diabetes mellitus: fasting and postprandial glucose in context.
Topics: Antihypertensive Agents; Blood Glucose; Blood Glucose Self-Monitoring; Carbamates; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Progression; Drug Therapy, Combination; Glyburide; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hyperglycemia; Hypoglycemic Agents; Metformin; Piperidines; Postprandial Period | 2004 |
Comparing the long-term cost-effectiveness of repaglinide plus metformin versus nateglinide plus metformin in type 2 diabetes patients with inadequate glycaemic control: an application of the CORE Diabetes Model in type 2 diabetes.
Topics: Carbamates; Cohort Studies; Computer Simulation; Cost of Illness; Cost-Benefit Analysis; Cyclohexanes; Decision Support Systems, Clinical; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Health Care Costs; Humans; Male; Metformin; Middle Aged; Models, Econometric; Nateglinide; Outcome Assessment, Health Care; Phenylalanine; Piperidines; Quality-Adjusted Life Years | 2004 |
Continuous glucose monitoring: physiologic and pathophysiologic significance.
Topics: Adolescent; Adult; Biomarkers; Blood Glucose; Blood Glucose Self-Monitoring; Carbamates; Circadian Rhythm; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Monitoring, Physiologic; Piperidines; Postprandial Period; Statistics as Topic; Treatment Outcome | 2004 |
Acute hepatotoxicity caused by repaglinide.
Topics: Aged; Carbamates; Chemical and Drug Induced Liver Injury; Diabetes Mellitus, Type 2; Humans; Hyperglycemia; Hypoglycemic Agents; Male; Piperidines | 2004 |
Treating type 2 diabetes. When diet and exercise aren't enough, a broad range of medications can help control our blood sugar.
Topics: Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Administration Schedule; Eating; Humans; Hypoglycemic Agents; Nateglinide; Phenylalanine; Piperidines | 2004 |
Accuracy of continuous nocturnal glucose screening after 48 and 72 hours in type 2 diabetes patients on combined oral and insulin therapy.
Topics: Administration, Oral; Aged; Body Mass Index; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Middle Aged; Monitoring, Ambulatory; Monitoring, Physiologic; Piperidines; Regression Analysis; Reproducibility of Results; Time Factors | 2004 |
Cholestatic hepatitis associated with repaglinide.
Topics: Aged; Carbamates; Chemical and Drug Induced Liver Injury; Cholestasis; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Male; Piperidines | 2005 |
Mild, reversible pancytopenia induced by rosiglitazone.
Topics: Carbamates; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Humans; Hypoglycemic Agents; Male; Middle Aged; Piperidines; Rosiglitazone; Thiazolidinediones | 2005 |
Oral agents in managing diabetes mellitus in children and adolescents.
Topics: Administration, Oral; Adolescent; Carbamates; Child; Clinical Trials as Topic; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Piperidines; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome | 2005 |
Safety profile of repaglinide as used in general practice in England: results of a prescription-event monitoring study.
Topics: Aged; Carbamates; Cause of Death; Cohort Studies; Diabetes Mellitus, Type 2; Drug Prescriptions; England; Family Practice; Female; Humans; Hypoglycemic Agents; Infant; Middle Aged; Piperidines; Pregnancy; Safety; State Medicine; Survival Analysis; Vision Disorders | 2006 |
A comparison of glycemic effects of glimepiride, repaglinide, and insulin glargine in type 2 diabetes mellitus during Ramadan fasting.
Topics: Adult; Body Mass Index; Carbamates; Diabetes Mellitus, Type 2; Fasting; Female; Fructosamine; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Islam; Male; Middle Aged; Patient Selection; Piperidines; Sulfonylurea Compounds; Turkey | 2007 |
Use of repaglinide during the first weeks of pregnancy in two type 2 diabetic women.
Topics: Adult; Carbamates; Diabetes Mellitus, Type 2; Female; Humans; Insulin; Piperidines; Pregnancy; Pregnancy in Diabetics; Pregnancy Trimester, First | 2006 |
Use of repaglinide on a pregnant woman during embryogenesis.
Topics: Adult; Carbamates; Diabetes Mellitus, Type 2; Embryonic Development; Female; Humans; Hypoglycemic Agents; Infant, Newborn; Maternal-Fetal Exchange; Piperidines; Pregnancy; Pregnancy in Diabetics | 2007 |
Achieving glycosylated hemoglobin targets using the combination of repaglinide and metformin in type 2 diabetes: a reanalysis of earlier data in terms of current targets.
Topics: Biomarkers; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Piperidines; Randomized Controlled Trials as Topic; Treatment Outcome | 2008 |
Severe hypoglycemia from clarithromycin-repaglinide drug interaction.
Topics: Aged, 80 and over; Anti-Bacterial Agents; Blood Glucose; Carbamates; Clarithromycin; Diabetes Mellitus, Type 2; Drug Interactions; Helicobacter Infections; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Piperidines | 2008 |
Repaglinide, glibenclamide and glimepiride administration to normal and hereditarily diabetic rats.
Topics: Administration, Oral; Animals; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Fasting; Female; Glyburide; Hypoglycemic Agents; Insulin; Male; Piperidines; Rats; Rats, Wistar; Sulfonylurea Compounds | 1997 |
Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes.
Topics: Animals; Binding Sites; Binding, Competitive; Blood Glucose; Carbamates; Cohort Studies; Culture Techniques; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Evoked Potentials; Glucose; Glyburide; Hypoglycemic Agents; Insulin; Insulin Secretion; Islets of Langerhans; Male; Mice; Mice, Inbred Strains; Osmolar Concentration; Patch-Clamp Techniques; Perfusion; Piperidines; Rats; Rats, Sprague-Dawley; Time Factors; Tritium | 1998 |
Repaglinide for type 2 diabetes mellitus.
Topics: Carbamates; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Fasting; Humans; Hypoglycemic Agents; Piperidines; Postprandial Period | 1998 |
Pancreatic islet responsiveness to D-glucose after repeated administration of repaglinide.
Topics: Administration, Oral; Animals; Blood Glucose; Carbamates; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Female; Glucose; Hypoglycemic Agents; Insulin; Islets of Langerhans; Piperidines; Rats; Rats, Wistar | 1998 |
Drug knowledge is critical.
Topics: Aged; Carbamates; Diabetes Mellitus, Type 2; Drug Interactions; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Piperidines | 1998 |
For diabetes: a preprandial pill ...
Topics: Carbamates; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Piperidines | 1998 |
[Flexible oral therapy of diabetes mellitus type 2: dietary glucose regulation as therapeutic principle. 34th annual session of the European Association for the Study of Diabetes (EASD). Barcelona, 8-12 September 1998].
Topics: Administration, Oral; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Diet, Diabetic; Glucose; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Piperidines | 1998 |
Pharmacokinetic profiles of repaglinide in elderly subjects with type 2 diabetes.
Topics: Aged; Carbamates; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Piperidines | 1999 |
Improving management of type 2 diabetes mellitus: 4. Meglitinides.
Topics: Carbamates; Contraindications; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Piperidines | 1999 |
Comments on type 2 diabetes screening and treatment.
Topics: Carbamates; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Hypoglycemic Agents; Piperidines | 2000 |
Managing type 2 diabetes. A look at the newer agents.
Topics: Acarbose; Carbamates; Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Piperidines; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
[Mechanisms of action of repaglinide at a cellular level].
Topics: Carbamates; Diabetes Mellitus, Type 2; Humans; Hyperglycemia; Hypoglycemic Agents; Inulin; Piperidines | 1999 |
[Insulin secretion and repaglinide].
Topics: Carbamates; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diet, Diabetic; Exercise; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Piperidines | 1999 |
[Repaglinide in combination therapy in type 2 diabetes].
Topics: Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Islets of Langerhans; Metformin; Piperidines | 1999 |
Repaglinide: a novel oral antidiabetic agent.
Topics: Administration, Oral; Blood Glucose; Body Weight; Carbamates; Diabetes Mellitus, Type 2; Humans; Hypoglycemia; Hypoglycemic Agents; Piperidines; Sulfonylurea Compounds | 2000 |
[Prandial glucose regulator for type 2 diabetic patients. Beta cells produce insulin according to need].
Topics: Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Islets of Langerhans; Piperidines | 1999 |
[Antidiabetic drug at every meal. Repaglinide is especially recommended for slender type 2 diabetic patients].
Topics: Blood Glucose; Carbamates; Diabetes Mellitus; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Hypoglycemic Agents; Obesity; Piperidines | 2000 |
Prandial glucose regulation with repaglinide: its clinical and lifestyle impact in a large cohort of patients with Type 2 diabetes.
Topics: Attitude to Health; Blood Glucose; Carbamates; Cohort Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Eating; Feeding Behavior; Female; Germany; Humans; Hypoglycemic Agents; Life Style; Male; Middle Aged; Piperidines; Professional Practice; Prospective Studies; Surveys and Questionnaires; Treatment Outcome; Weight Loss | 2000 |
Honing type 2 diabetes treatment.
Topics: Carbamates; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Piperidines; Thiazoles; Thiazolidinediones | 2001 |
Insulin secretagogues.
Topics: Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Piperidines | 1997 |
[Large general practice study with repaglinide. Fewer "anxiety eating" in diabetic patients].
Topics: Carbamates; Diabetes Mellitus, Type 2; Diet, Diabetic; Feeding Behavior; Humans; Hypoglycemic Agents; Patient Compliance; Piperidines | 2001 |
[Repaglinide].
Topics: Carbamates; Diabetes Mellitus, Type 2; Half-Life; Humans; Hypoglycemic Agents; Insulin; Piperidines; Structure-Activity Relationship | 2001 |
A new era in type 2 diabetes mellitus treatment?
Topics: 1-Deoxynojirimycin; Acarbose; Carbamates; Diabetes Mellitus, Type 2; Glucosamine; Humans; Hypoglycemic Agents; Imino Pyranoses; Multicenter Studies as Topic; Pioglitazone; Piperidines; Randomized Controlled Trials as Topic; Thiazoles; Thiazolidinediones | 2001 |
Repaglinide dose response? A clinician's viewpoint.
Topics: Blood Glucose; C-Peptide; Carbamates; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Humans; Hypoglycemic Agents; Insulin; Piperidines | 2000 |
Utilization of oral hypoglycemic agents in a drug-insured U.S. population.
Topics: Carbamates; Chromans; Cohort Studies; Databases as Topic; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Insurance, Pharmaceutical Services; Longitudinal Studies; Managed Care Programs; Metformin; Piperidines; Retrospective Studies; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Time Factors; Troglitazone; United States | 2001 |
Repaglinide dose response? A clinician's viewpoint.
Topics: Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Exercise; Humans; Hyperglycemia; Hypoglycemic Agents; Piperidines; Weight Loss | 1999 |
The importance of rapid insulin secretion: revisited.
Topics: Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Homeostasis; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Piperidines | 1999 |
[Pharma-clinics. Medication of the month. Repaglinide (NovoNorm)].
Topics: Administration, Oral; Carbamates; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Humans; Hypoglycemic Agents; Piperidines; Postprandial Period | 2001 |
Effect of repaglinide addition to NPH insulin monotherapy on glycemic control in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Insulin, Isophane; Male; Middle Aged; Piperidines | 2001 |
[Therapy of type 2 diabetes. Avoiding postprandial blood glucose peaks!].
Topics: Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Drug Administration Schedule; Humans; Piperidines; Postprandial Period | 2001 |
Type 2 diabetes management.
Topics: Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Metformin; Nateglinide; Phenylalanine; Piperidines | 2002 |